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Abstract 
	  
Tuberculosis (TB) is one of the foremost infectious diseases worldwide, with over 9 
million new cases reported in 2013. The outcome of TB infection depends on the 
interplay between the host defence response and its evasion by Mycobacterium 
tuberculosis. TB is acquired as a respiratory infection with lung macrophages the 
primary host cell infected. Activation of these macrophages is essential to contain the 
bacilli. The discovery of miRNAs in 1993 has opened a new door to acquire a deeper 
understanding how the response to M. tuberculosis infection is regulated. Emerging 
evidence has shown that microRNAs are pivotal in the regulation of the immune 
system. 
Dysregulation of miRNAs has been associated with a wide spectrum of human 
diseases. Recent publications have demonstrated that mycobacterial infection also 
modulates the expression of miRNAs, which themselves regulate the activation of 
many macrophage genes. Overall though the influence of mycobacterial infection on 
miRNA expression has not been well defined. 
This study investigated how mycobacterial infection modulates the miRNA 
expression profile in murine alveolar (AMJ2.C11) and peritoneal (IC-21) macrophage 
cell lines. The effect on bacterial virulence on miRNA expression was also examined 
by comparing infection with virulent M. tuberculosis and the vaccine strain M. bovis 
BCG. 
M. tuberculosis infection induced different patterns of miRNAs expression in the two 
macrophage cell lines. The IC-21 peritoneal macrophage line showed rapid miRNAs 
upregulation with levels peaking at two to six hours post infection and then generally 
returning to the baseline seen in uninfected cells within 24 hours. In contrast, the 
upregulation of miRNAs in the AMJ2.C11 alveolar macrophage line was slower with 
levels peaking around 24 hours post infection with most remaining elevated after 48 
hours. Despite the marked difference in miRNAs expression profiles, these 
macrophages shared a similar proinflammatory cytokine and chemokine response to 
infection. However, AMJ2.C11 macrophages showed an increased bacterial killing 
ability compared with IC-21 macrophages, though further research is required to 
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determine if there is a correlation between the capability of bacterial killing and the 
differential miRNAs expression profile seen in these two infection models. 
The effect of one of these miRNA in regulating immunity to M. tuberculosis was 
further examined, by inhibiting or overexpressing miR-146a in both cell lines. These 
data show that inhibition of miR-146a led to a small but significant reduction in 
bacterial load in the AMJ2.C11 alveolar, but not the IC-21 peritoneal, macrophages. 
Overexpression of miR-146a did not significantly impact bacterial growth. miR-146a 
is reportedly a negative regulator of inflammation, however in these studies inhibition 
of miR-146a did not lead to any major changes in the expression of a range of 
proinflammatory cytokines and chemokines including TNF, RANTES and MCP-1. 
How miR-146a inhibition may be enhancing mycobacterial killing remains to be 
determined. 
Determining how miRNAs regulate immunity to M. tuberculosis may identify new 
targets for future therapeutic intervention. This study has established a new route to 
further investigate the significance of miRNAs including miR-146a in regulating host 
immunity to tuberculosis. 
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1.1 Tuberculosis: General overview 
Tuberculosis (TB) is an airborne infectious disease caused by Mycobacterium 
tuberculosis, affecting one-third of the world’s population, with 9 million new cases 
each year and 1.5 million deaths reported in 2013 (World-Health-Organization, 2014). 
An estimated 530,000 TB cases were reported in children under age of 15 in 2012 
(World-Health-Organization, 2014). Tuberculosis is primarily a pulmonary disease as 
tubercle bacilli thrive in the oxygen-rich upper lobes of the lungs. However, 
tuberculosis can disseminate via haematogenous spread throughout the body, 
infecting any organ in the body including brain, bone and kidney (Raviglione and 
O'Brien, 2012). Active clinical TB can present as a primary infection, particularly in 
children and immunodeficient patients, or secondary (reactivation) infection. 
 
Historical records show that TB was a poverty related disease that thrived in the 
overcrowding and poor living standards of the industrial era, when this infectious 
disease caused enormous number of deaths in Europe (Lawn and Zumla, 2011). In the 
present day, the geographical distribution of TB cases centres in highly populated 
resource-poor developing countries where malnourishment, poor sanitation and low 
standard of living exacerbates the spread of tuberculosis. Low and middle-income 
countries account for 80% of worldwide TB cases (Raviglione and O'Brien, 2012).  In 
2012 the World Health Organisation (WHO) reported the majority of TB cases were 
in South-East Asia (29%), sub-Saharan Africa (27%), and Eastern Europe (Lawn and 
Zumla, 2011, World-Health-Organization, 2014). 
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Despite being a curable disease, tuberculosis remains a major global health threat. The 
rising number of HIV cases and the increasing spread of multidrug resistant TB 
undermine global TB control programmes. In 2012, the WHO reported an estimated 
1.1 million people with TB and HIV coinfection (13% of total worldwide TB cases), 
with 75% of these cases in Africa (World-Health-Organization, 2014).  Another 
compounding factor is poor compliance with treatment, which is attributed to the long 
course of drug therapy, requiring a minimum 6 months of cocktail therapy, and the 
difficulty individuals face to reach healthcare providers in some remote areas in poor 
developing countries. As a result, the improper or incomplete treatment regime often 
leads to the emergence of multidrug-resistant tuberculosis (MDR-TB). 
1.2 Microbiology of Mycobacteria tuberculosis 
Mycobacterium tuberculosis is a member of the Mycobacteria family. Mycobacteria 
are aerobic, non-spore-forming and non-motile bacilli, with a unique bacterial cell 
wall composed of peptidoglycan and complex lipids (Murray et al., 2012). The lipid 
components contribute to the hydrophobic properties, antibiotic resistance and 
virulence determinants of Mycobacteria. Although 150 species of Mycobacteria have 
been identified, only a few species are major pathogens of human diseases: 
Mycobacterium tuberculosis, Mycobacterium leprae and Mycobacterium avium 
complex (Murray et al., 2012).  
 
The physical property that distinguishes mycobacteria from either Gram-positive or -
negative pathogens is their lipid-rich wall that resists the decolourization by acids 
during the standard staining techniques, hence, known as acid-fast bacilli (Lawn and 
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Zumla, 2011). Ziehl–Neelsen stain is a special staining procedure for mycobacteria by 
using Carbol fuchsin to stain the waxy lipid wall followed by destaining with 
hydrochloric acid in isopropyl alcohol. Acid-fast bacilli appear in bright red with 
methylene blue-stained cells as background (Murray et al., 2012). 
1.3 Pathogenesis of Tuberculosis  
1.3.1 Transmission and risk factors 
M. tuberculosis (M. tb) is transmitted via aerolised droplets (<5–10 µm in diameter) 
generated by people with active disease (Raviglione and O'Brien, 2012). The intimacy 
and duration of contact with patients with active TB and the degree of infectiousness 
of the patients determine the rate of disease transmission. Approximately 105-107 
bacilli/mL of sputum can be found in patients with open cavitary TB (Raviglione and 
O'Brien, 2012). Although the mucocilliary epithelial lining of the upper respiratory 
tract provides a protective barrier against the inhaled aerosol droplets, a small portion 
of the infectious droplets can still travel down to the respiratory bronchioles. 
 
During the primary infection, most immunocompetent individuals either eliminate or 
contain M. tuberculosis in a latent state. The estimated lifetime risk of an individual 
developing active clinical TB is only 10% (Lawn and Zumla, 2011). An estimated 
one-third of the world’s population have latent TB infection (World-Health-
Organization, 2014). The latent infection serves as a reservoir for potential diseases, 
which can be reactivated when the host immune system is compromised. Among co-
morbidities, HIV infection is the most potent risk factor for TB transmission, 
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individuals with HIV have a 20-times greater risk of developing active disease than 
the non-HIV infected population (Houben et al., 2010). 
1.3.2 Host-pathogen interaction 
The interaction between M. tuberculosis and host defence mechanisms determines the 
fate of disease progression. Our understanding of how M. tuberculosis and the host 
immune response interact to maintain a balanced state is poorly understood. Upon 
first exposure to M. tuberculosis, resident alveolar phagocytic cells ingest the bacilli 
and try to destroy them, while attracting blood-derived monocytes and other 
inflammatory cells to the site of infection. Dendritic cells initiate and direct the 
activation of an antigen-specific T cell response which is first evident around 2-3 
weeks after primary infection. Activated T cells activate phagocytic cells to restrict 
bacterial growth at the lesion site. With the recruitment of additional inflammatory 
cells granulomas form to contain the bacilli (van Crevel et al., 2002). M. tuberculosis 
can remain in a dormant state for years indeed for an individual entire lifetime, unless 
the host’s immunity weakens allowing the bacteria to grow uncontrolled. The 
resulting weakened immune response leads to liquefied caseous necrosis and the 
breakdown of granulomas, allowing the presence of oxygen that favours M. 
tuberculosis growth (Flynn and Chan, 2001). Cavitary lesions are susceptible to 
rupture, resulting in the spread of bacteria to the airways, other pulmonary sites and 
haematogenous dissemination.  
1.4 Immune responses to M. tuberculosis  infection 
1.4.1 The role of macrophages in innate immunity   
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M. tuberculosis  is taken up of by lung macrophages and dendritic cells through the 
process of phagocytosis, following immune recognition (Murray et al., 2012). 
Complement receptors mediate uptake of the opsonized M. tuberculosis, whereas 
mannose receptors and scavenger receptors bind non-opsonized M. tuberculosis 
(Flynn and Chan, 2001). Macrophages exert a range of anti-mycobacterial functions 
including fusion of the bacteria carrying phagosome with lysosomes, which utilizes 
acidification by lysosomal hydrolases to destroy the pathogen (Fenton and Vermeulen, 
1996). M. tuberculosis employs several strategies to survive from intracellular 
destruction including the inhibition of phagolysosomal fusion, alteration of 
phagolysosomal pH and inactivation of lysosomal enzymes. The surviving bacilli can 
multiply leading to the disruption of infected macrophages and subsequent infection 
of other cells. Meanwhile, blood-derived monocytes and other inflammatory cells are 
recruited to the site of infection, and these monocytes differentiate into tissue-resident 
macrophages to help contain the bacterial growth. 
 
In addition to phagocytosis, immune recognition of M. tuberculosis is pivotal to 
stimulate effective activation of the innate immune system, which interacts with 
components of the adaptive immune system to contain the mycobacterial infection. 
Toll-like receptors (TLRs) are transmembrane proteins important for M. tuberculosis 
recognition on macrophages and dendritic cells. TLR-2 recognises lipoarabinomannan 
(LAM), a major component of M. tuberculosis lipid cell wall, and lipoprotein. TLR-4 
binds with heat-labile cell-associated mycobacterial factor, and TLR-9 recognises M. 
tuberculosis bacterial DNA (Kaufmann, 2001, Jones et al., 2001). Activation of these 
pattern recognition receptors stimulates a signal transduction cascade through MyD88 
(myeloid differentiation protein 88), an adapter protein that links TLRs to IRAK (IL-
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1R-associated kinase) and activates the NFκB pathway that induces the production of 
multiple proinflammatory cytokines, including tumour necrosis factor alpha (TNF), 
interferon-γ (IFN-γ) and IL-12 (Kaufmann, 2002).  A mutation on TLR-2 has been 
shown to inhibit TNF release in a murine macrophage cell line (RAW-TT10) upon the 
exposure to M. tuberculosis (Underhill et al., 1999), indicating that activation of the 
TLR is important for an optimal response to M. tuberculosis infection. 
 
TNF and IFN-γ act synergistically to activate macrophage antibacterial mechanisms 
including the production of reactive nitrogen intermediates (RNI) and reactive oxygen 
intermediates (ROI) (Flesch and Kaufmann, 1990). Both phagocytosis and TLR-
dependent recognition are required for immune activation and this coordinated 
process enhances the antibacterial properties of the macrophages to stimulate effective 
mycobacterial killing (Kaufmann, 2001). 
 
1.4.2 A consequence of macrophage activation: Role of Reactive 
Oxygen Intermediates (ROI) and the Nitrogen Oxides (NO) 
Following the activation of macrophages by TNF and IFN-γ, macrophage bactericidal 
activities are upregulated. One of these mechanisms involves converting molecular 
oxygen into ROI such as hydrogen peroxide (H2O2), and producing nitric oxides via 
nitrogen oxide synthase (NOS2) using L-arginine as a substrate (MacMicking et al., 
1997). The importance of ROI and RNI in anti-mycobacterial mechanisms to control 
M. tuberculosis infection has been demonstrated in ROI and RNI knockout mice 
(Cooper et al., 2000). Although the role of reactive nitrogen intermediates (RNI) is 
not well established in human studies, the presence of high level of NOS2 in 
bronchoalveolar lavage from patients with active TB and the high content of NO 
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exhaled by the patients suggest that RNI may have protective roles against TB 
infection (Nicholson et al., 1996). 
Activated macrophages release a large range of cytokines and chemokines including; 
RANTES (regulated upon activation, normal T cell expressed and secreted), MCP-1 
(monocyte chemoattractant protein-1), IP-10 (interferon-inducible protein-10) and 
MIP-1α/β (macrophage inflammatory protein-1 alpha/beta). These are essential to 
orchestrate the recruitment of inflammatory cells including circulating T cells, 
monocytes and neutrophils essential to confine the M. tuberculosis infected cells and 
contain bacterial growth (Saunders and Britton, 2007). The recruitment process is also 
fortified by the upregulation of chemokine receptor CCR2 and CCR5 to direct other 
inflammatory cells to the inflammation loci (Flynn and Chan, 2001). 
 
1.4.3 T cells responses to Mycobacterium tuberculosis 
After the recognition of antigenic peptides both CD4+ and CD8+ T cells are activated 
and contribute to the development of protective immunity against M. tuberculosis. IL-
12 driven Th1 CD4+ T cells produce cytokines including, IL-2, TNF, and IFN-ɣ which 
are essential macrophage activators (Kaufmann, 2001). The importance of CD4+ T 
cells is clearly demonstrated in HIV infected individuals, where the depletion of CD4+ 
T cells increases their susceptibility for developing active TB disease from a 10% 
lifetime risk to a 10% annual risk (van der Ende et al., 1999, Selwyn et al., 1989).  
 
Although the significant contribution of CD4+ T cells to the control of M. tuberculosis 
is well established, MHC class I-restricted CD8+ T cells also have a role to play in 
controlling this intracellular pathogen. Under IL-12 stimulation, CD8+ T cells 
	  
	  
8	  
	  
differentiate into cytotoxic T lymphocytes (CTL), which can lyse infected target cells 
by perforin and granzymes via the Fas/FasL pathway. Perforin is required to form 
pores and granulysin kills the intracellular bacteria (Stenger et al., 1998, Stenger et al., 
1997). In addition, CTLs also contribute to IFN-ɣ production thereby aiding 
macrophage activation (Feng et al., 1999). A study in transporter associated with 
antigen processing (TAP)1-deficient mice showed that when MHC class I molecules 
were unable to present mycobacterial peptides to CD8+ T cells, M. tuberculosis-
infected mice developed severe pathological damage and increased bacterial burden 
(Behar et al., 1999). 
1.5 The survival mechanisms of M. tuberculosis against host 
immunity 
Despite the presence of innate and adaptive immunity, M. tuberculosis is endowed 
with a plethora of mechanisms to evade host immune responses. To survive the toxic 
free radical molecules produced by activated macrophages, M. tuberculosis generates 
KatG, a catalase-peroxidase, to inactivate ROI, and the mycobacterial proteasome 
neutralizes the toxic effect of NO by refolding damaged proteins (Pieters, 2008). In 
addition, LAM and phenolicglycolipid I (PGL-I) components of the mycobacterial 
cell wall are potent oxygen radical scavengers (Flynn and Chan, 2001).  
 
To evade hydrolytic enzymes, mycobacterial glycolipids can block phagolysosomal 
fusion by interfering with host trafficking events involving phosphatidylinositol 3-
phosphate (PIP-3). PIP-3 is an essential component of docking sites for several 
proteins during the phagosome and lysosome fusion process. LAM is also believed to 
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interfere with the biosynthesis of PIP-3 by inhibiting PI3 kinase hVP34 (Vergne et al., 
2003). M. tuberculosis produces eukaryotic-like phosphatase (SapM) which 
hydrolizes PIP3 on phagosomal membranes (Saleh and Belisle, 2000, Vergne et al., 
2005). Despite a lack of understanding of the precise mechanism, mycobacterial 
serine/threonine kinase PknG appears to modulate signal transduction cascades, 
resulting in the prevention of phagoslysosomal fusion (Nguyen and Pieters, 2005).  
 
Another strategy employed by M. tuberculosis to avoid lysosomes is the recruitment 
of coronin 1 protein, also known as TACO (tryptophan aspartate containing coat 
protein) during entry to phagosomes (Jayachandran et al., 2007, Pieters, 2008). 
Coronin 1 retention allows the cytosolic influx of calcium, which activates calcium-
dependent phosphatase calcineurin, leading to the blocking of phagolysosomal fusion. 
This finding is supported by the inhibition of mycobacterial proliferation in 
phagosomes under the administration of calcineurin blockers cyclosporine and FK506 
(Jayachandran et al., 2007). 
1.6 Current problems with TB diagnosis 
The so-called gold–standard diagnostic test for TB is sputum culture, unfortunately 
this can take up to 2 months to yield a result due to the slow growth rate of M. 
tuberculosis. Furthermore, this laboratory-based method is often not available in 
resource-poor settings, leaving Ziehl-Neelsen–stained sputum examined under light 
microscopic as the only available diagnostic test (McNerney et al., 2012). The 
accuracy of this test is complicated by the difficulty in obtaining an adequate sputum 
sample. This is especially difficult in children and immunosuppressed individuals 
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such as HIV patients, potentially delaying TB diagnosis, the commencement of 
antibiotic intervention, and leading to the spread of tuberculosis. In addition, both 
sputum culture and smear fail to detect extrapulmonary TB infection. As most 
transmission occurs during the period between the onset of cough and the initiation of 
treatment, delay in diagnosis hinders disease control (Storla et al., 2008). Other 
factors complicating TB diagnosis include concurrent chronic cough or lung diseases, 
and a lack of access to health provider (Storla et al., 2008).   
 
In the past decade, some advances have been achieved in diagnostic methods to 
identify TB including the nucleic acid amplification (NAAT) GeneXpert MTB/RIF® 
assay which detects M. tuberculosis infection including Rifampicin-resistant strains of 
M. tuberculosis by targeting the rpoB gene. The test is accurate, rapid, and able to 
detect 57%-83% of smear-negative active TB (Boehme et al., 2011). GeneXpert 
MTB/RIF can be used to diagnose extra-pulmonary TB and has no cross-reaction with 
non-tuberculous Mycobacterium.  Although GeneXpert MTB/RIF has value as a 
point-of-care diagnostic tool for drug-sensitive and drug-resistant M. tuberculosis, the 
current WHO guidelines only endorse the use of NAAT as an add-on test following 
smear microscopy in resource-limited settings. The cost of the GeneXpert MTB/RIF 
test is also an inhibiting factor in its use in resource-limited regions (Van Rie et al., 
2010, World-Health-Organization, 2014).  
 
Other significant inventions in TB diagnosis are interferon gamma release assays 
(IGRAs), QuantiFERON-TB Gold I-Tube assay (QFR-GIT) and T-SPOT.TB. These 
assays measure the IFN-ɣ release by T cells following incubation of patient blood 
with the M. tuberculosis antigen, early secretory antigenic target-6 (ESAT-6) and 
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culture filtrate protein 10 (CFP-10). These two antigens are specific to M. tuberculosis 
and not found in the vaccine strain M. bovis BCG. Despite the high specificity, IGRAs 
are not able to differentiate latent TB infection from active disease and their 
performance is not significantly superior to tuberculin skin tests (TSTs) in HIV 
individuals due to the depletion of IFNɣ-producing Th1 cells (Cattamanchi et al., 
2011, Wallis et al., 2013). 
 
Deficiencies in our understanding of how TB and host immunity maintain a balance 
complicates the urgent need for rapid, accurate and affordable TB diagnostic tools. It 
would be ideal if new point-of-care tests could be used to diagnose TB and monitor 
the response to antibiotic therapy, replacing the current 2-month sputum culture 
conversion test which can take more than 8 weeks for the result, and is not available 
in many regions.  As the TB burden is higher in low-income areas, the ideal point-of-
care TB tests should be easy to administer, simple, rapid, robust, and affordable and 
be able to detect both pulmonary and extra-pulmonary TB (McNerney et al., 2012).  
1.7 Biomarkers for Tuberculosis 
A biological marker or biomarker is a characteristic which is objectively measured 
and evaluated to provide accurate information regarding a physiological or pathogenic 
process, or pharmacological response to a therapeutic intervention (Group., 2001). 
The ideal biomarkers can serve as surrogates of disease which are statistically and 
pathophysiologically associated with the final outcome of the disease (Parida and 
Kaufmann, 2010). Diagnosis of TB disease lacks accurate and rapid diagnostic tests. 
New novel biomarkers would be valuable to classify patients as having active disease, 
latent infection or no disease. Moreover, biomarkers could be used to monitor drug 
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and vaccine trials, treatment responses and relapses, or predict reactivation from 
latency (Wallis et al., 2010).  Although the quest of discovering novel biomarkers for 
tuberculosis is challenging, several studies examining expression profiles are 
underway including transcriptomics, proteomics and microRNAs (Walzl et al., 2011).  
 
1.8 MicroRNAs 
MicroRNAs (miRNAs) are small highly conserved non-coding RNA molecules, 21-
25 nucleotides in length, which modulate their target gene expression at the post-
transcriptional level. miRNAs dominate the major portion of small RNAs which are 
also composed of miRNAs, siRNA and PIWI-interacting RNA (piRNAs), 
characterized as 20-30 nucleotides in length, and associated with Argonaute family 
proteins (AGO) as effectors in RNA silencing complex (Ha and Kim, 2014). 
 
The first identified miRNA was lin-4, identified in Caenorhabditis elegans (Lee et al., 
1993). This miRNA controls the developmental timing of larvae. This gene produces 
small non-coding RNAs that have antisense complementarity to the region of the 
3’UTR of the lin-14 gene. The base pairing of lin-4 miRNA to lin-14 leads to the 
translational repression of the lin-14 gene at the end of first larval stage (L1), resulting 
in the initiation of cell division to progress to the next developmental stage (L2) (Lee 
et al., 1993, Bartel, 2004). Conversely, mutations in lin-4 lead to the reiteration of 
certain cell-division patterns of L1 larval stage at later developmental stages (Chalfie 
et al., 1981).  
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The discovery of miRNA in C. elegans lead to the discovery of miRNA in humans, 
and indeed in all species examined to date. It is estimated that around 1–4% of genes 
in the human genome are miRNAs (Lu et al., 2008). Computer modelling and targeted 
studies have shown that a single miRNA can bind to hundreds of mRNA targets and 
exert multiple effects depending upon the target cell and the stage of activation (Lu et 
al., 2008). This discovery has lead to the determination that the dysregulation of 
miRNAs is associated with many human diseases including malignancies, heart 
diseases and diabetes (Knezevic et al., 2015, Arner and Kulyte, 2015, Krenning et al., 
2010, Rome, 2013). As current studies have revealed the correlation between 
miRNAs and human diseases, miRNAs might have potential as diagnostic and 
prognostic biomarkers. 
1.8.1 The biogenesis of microRNAs 
Nearly 1000 of miRNAs have been identified in recent years. The study of miRNAs 
has already identified multiple regulatory functions performed by miRNAs on gene 
expression resulting in a complex range of modulation of cell biology. It is well 
documented that miRNAs target hundreds of genes involved in a wide spectrum of 
cell biology including DNA repair, apoptosis and cell growth (He et al., 2007, Lal et 
al., 2009, Ambros, 2004). The biogenesis of mature miRNAs consists of multiple 
maturation steps from the nucleus to the cytoplasm (Figure 1.1). At the nuclear 
processing stage, miRNA genes that are encoded by the introns of protein-coding and 
non-coding genes are transcribed by RNA polymerase II into primary miRNAs (pri-
miRNAs) (Lee et al., 2004). pri-miRNAs contain two single-stranded RNA segments, 
a stem of 33-35 base pairs and a terminal loop in which the mature sequence of 
miRNAs are embedded (Ha and Kim, 2014). Following transcription, the stem-loop 
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of pri-miRNAs are cleaved by a nuclear microprocessor complex formed by the 
RNase III enzyme Drosha and DGCR8 (DiGeorge critical region 8). This releases a 
small hairpin-like structure RNA known as precursor miRNAs (pre-miRNAs), which 
is ~65 nucleotides in length. Pre-miRNA is exported by Exportin-5–Ran-GTP into the 
cytoplasm where Dicer, an RNase III endonuclease, cleaves the hairpin structure near 
the terminal loop, releasing an imperfect miRNAs duplex (miRNA:miRNA*), ranging 
from 21 to 25 nucleotides (Lee et al., 2003). This duplex comprises the mature 
miRNA strand and its complimentary or passenger strand (miRNA*) (Bartel, 2004). 
The small miRNA duplex is unwinding so that a single strand miRNA can be 
incorporated onto the AGO proteins to form the RNA-induced silencing complex 
(RISC). The relatively thermodynamic unstable terminus at 5’ end of the mature 
miRNA allows its preferential incorporation into the complex to generate a mature 
RISC (He and Hannon, 2004), liberating the miRNA to be released from the 
complimentary strand which is subsequently degraded. The mature RISC complex 
stabilizes the small structure of mature miRNAs as their termini are protected by the 
AGO proteins (Ha and Kim, 2014).  Despite the remarkable progression of knowledge 
about miRNAs, little is known about miRNA turnover.   
1.8.2 MicroRNAs in Tuberculosis 
As knowledge on the interplay between miRNAs and human diseases has become 
clearer, there is growing evidence that miRNAs are involved in mycobacterial 
infection. In leprosy lesions, expression profiling studies have revealed 13 miRNAs 
highly expressed in lepromatous leprosy versus tuberculous leprosy lesions (Mehta 
and Liu, 2014). One of these miRNAs is miR-21 the most highly expressed 
microRNA in lepromatous leprosy lesions (Liu et al., 2012). miR-21 targets multiple 
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genes in the vitamin D antimicrobial pathway by reducing the expression of IL-1β and 
CYP27B1 in macrophages during M. tuberculosis infection (Mehta and Liu, 2014). 
Functional studies have shown that miR-21 has the ability to reduce TLR2/1-triggered 
anti-mycobacterial activity and inhibit IL-12p35 expression, resulting in the skewing 
of Th1 to Th2 T-cell response in leprosy (Lu et al., 2009).   
 
M. tuberculosis-infection of human macrophages also modifies miRNA expression. 
Infected macrophages were shown to have high expression of miR-125b but low 
expression of miR-155 (Rajaram et al., 2011, Tili et al., 2007). miR-125b targets and 
destabilizes TNF mRNA while miR-155 enhances TNF production (Tili et al., 2007). 
In support of the relationship between these miRNAs and TNF, the downregulation of 
miR-125 has been observed in skin psoriasis associated with high levels of TNF, and 
the overexpression of miR-155 in mouse macrophages leads to an increase in 
mycobacterial killing via TNF (Kumar et al., 2012, Sonkoly et al., 2007). The 
differential expression of miR-125 and miR-155 in M. tuberculosis-infected human 
macrophages, therefore, maybe implicated in controlling the level of TNF production.  
 
The expression of miRNAs in macrophages following mycobacterial infection may 
change during the course of infection. M. bovis BCG infection induced high levels of 
miR-31, miR-150 and miR-146a in murine macrophages 72 hours post infection 
(Ghorpade et al., 2013). Conversely, active TB patients have significantly low levels 
of the human homolog of the same miRNAs in peripheral blood mononuclear cells 
cultured from buffy coats compared to healthy controls (Ghorpade et al., 2013). miR-
146a and miR-150 are believed to control chronic inflammation by targeting the TLR 
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signalling cascade (Taganov et al., 2006). The differential expression of microRNAs 
might, thus influence the outcome of infection based on the immune cascade targeted 
by miRNAs (Mehta and Liu, 2014). 
1.8.3 microRNA 146  
miR-146 is found in low levels in naïve T cells and upregulated in Th1 cells (Saba et 
al., 2014). The upregulation of miR-146 was reported in human and murine 
macrophages following LPS stimulation (Taganov et al., 2006, Li et al., 2013). It has 
been well documented that the induction of miR-146 by LPS is regulated by TLR4 
and is NF-κB dependent (Taganov et al., 2006). The upregulation of miR-146, 
however is believed to act as a fine-tuning mechanism to prevent an unrestrained 
inflammatory response (Saba et al., 2014). 
 
In vivo and in vitro studies have shown that miR-146a negatively regulates TLR-
signalling pathways by directly targeting IRAK1 and TNF receptor-associated factor 
6 (TRAF6), leading to the suppression of NF-κB (Taganov et al., 2006, Hou et al., 
2009). As a result, the induction of NF-κB-dependent pro-inflammatory cytokines 
including TNF, IL-6 and IL-1β is inhibited. miR-146a also downregulates the 
production of chemokines RANTES and IL-8 in human alveolar A549 epithelial cells 
study (Perry et al., 2008).  
 
Interestingly, miRNAs not only regulate macrophages to M. tuberculosis infection, 
they also regulate other immune cells. A recent study showed that M. bovis BCG 
infection in mice induced the downregulation of miR-29 in Th1 cells. miR-29 was 
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found to be able to inhibit the production of IFNɣ by Th1 cells at the post-
transcriptional level, thereby also suppressing the immune response against 
intracellular pathogens (Ma et al., 2011b). Another study showed M. tuberculosis 
modulates the immune response in dendritic cells by stimulating the expression of 
miR-99b which can suppress pro-inflammatory cytokines such as IL-6, IL-12 and IL-
1β (Singh et al., 2012). 
 
Increasing our understanding of the role of miRNAs in TB will likely open up new 
avenues for the identification for M. tuberculosis novel biomarkers to aid TB 
diagnosis and to monitor and predict the outcome of M. tuberculosis infection. 
1.9 Aims and hypotheses 
The aims of this study are: 
(i) To compare the expression profiles of selected miRNAs in murine alveolar 
macrophages (AMJ2.C11) with peritoneal macrophages (IC-21) following 
infection with the vaccine strain M. bovis BCG and virulent M. 
tuberculosis. 
(ii) To compare the inflammatory response of murine alveolar and peritoneal 
macrophages following infection with M. bovis BCG and M. tuberculosis. 
(iii) To study the functional effects of silencing and overexpressing miR-146a 
in murine macrophages on immune function and control of M. tuberculosis 
infection.  
The hypotheses of the study are: 
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(i) M. bovis BCG and M. tuberculosis differentially modulate expression of 
multiple miRNA in murine macrophages. 
(ii) Alveolar and peritoneal macrophages show variation in their inflammatory 
response to mycobacterial infection.  
(iii) Inhibition of miR-146a will enhance macrophage inflammatory activity 
and reduce the survival of intracellular bacteria, whereas overexpression of 
miR-146a will reduce the production of inflammatory cytokines, resulting 
in an increase in mycobacterial growth. 
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2.1 Materials 
2.1.1 General chemicals and buffers 
All chemical reagents were purchased from BDH Chemicals (Melbourne, Australia) 
unless otherwise specified.  
• Phosphate buffered saline, pH 7.2 (PBS): 8 g NaCl, 0.2 g KCl, 1.44 g 
Na2HPO4 and 0.24 g KH2PO4 dissolved in 1 L triple distilled water (TDW).  
PBS is sterilized by autoclaving at 121oC for 20 min and kept at room 
temperature. 
• PBS/Tween, 0.05 % (v/v) (PBST): 5 ml Tween-20 (Sigma, St. Louis, MO) in 
10 L PBS. 
• Carbonate buffer, pH 9.1: 7.56 g NaHCO3 and 2.86 g Na2CO3 dissolved in 1 
L TDW and adjusted the pH to 9.1 with 1 M HCl. 
• 10x Citrate Buffer pH 4.5: 215 g citric acid (Sigma), 150 g tri-sodium citrate 
(Sigma), 1L TDW, and adjusted pH to 4.5 with 1 M HCl.  
• 10x 2,2’-azino-bis(3-ethylbenzthiazoline-6-sulfonic acid) (ABTS): 1 g 
ABTS (Sigma) dissolved in 100 ml TDW, filter sterilized and stored at 4 ⁰C.  
 
2.1.2 Tissue culture media 
• 2-mercaptoethanol (2-ME) free RPMI media 
RPMI 1640 medium (Life Technologies, Victoria, Australia) consisting of L-
glutamine and 25 mM HEPES was supplemented with 10 % (v/v) foetal calf serum 
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(FCS) (Scientifix Life, Clayton, Australia) and 1% (v/v) penicillin (100 U/ml) and 
streptomycin (100 µg/ml). 
• 2-mercaptoethanol (2-ME) free DMEM media 
DMEM medium (Life Technologies, Victoria, Australia) consisting of L-glutamine, 
4.5 g/L D-Glucose and 25 mM HEPES was supplemented with 10 % (v/v) FCS and 1 
% (v/v) penicillin (100 U/ml) and streptomycin (100 µg/ml). 
 
2.1.3 Cell lines 
• AMJ2.C11 (ATCC CRL-2456): Alveolar macrophage cell line generated 
from a C57BL6 mouse by in vitro infection with J2 retrovirus carrying the v-
raf and v-myc oncogenes. Cells are non-adherent and cultured in 6-well plates 
(Becton Dickinson) with 2-ME-free DMEM media.  
• IC-21 (ATCC TIB-186):  Peritoneal macrophage cell line generated from 
transformation of C57BL6 mouse peritoneal macrophages with SV40. Cells 
are adherent and cultured in 6-well plates (Becton Dickinson) with 2-ME-free 
RPMI media. 
 
2.1.4 Bacteria 
• Mycobacterium tuberculosis: H37Rv (ATCC 27294) stocks were stored in 
30% (v/v) glycerol/PBS at -70⁰C.  
	  
	  
22	  
	  
• Mycobacterium bovis Bacille Calmette-Guerin: M. bovis BCG (Aventis 
Pasteur, Lyon, France). Bacteria stocks were stored at -70 ⁰C in 30% (v/v) 
glycerol/PBS.  
 
2.1.5 Bacterial culture media 
• Oleic acid albumin dextrose catalase (OADC) enrichment: 50 mg oleic 
acid (Sigma), 5 g bovine serum albumin (BSA) (ICN Biomedicals, Aurora, 
OH), 2 g dextrose (Sigma), 4 mg catalase (Sigma) and 0.85 g NaCl (Amresco, 
Ohio, USA) dissolved in 100 ml TDW, and filter sterilized through 0.2 µM 
filter.  
• Albumin dextrose catalase (ADC) enrichment: 5 g BSA, 2 g dextrose and 3 
mg catalase dissolved in 100 ml TDW and filter sterilized through 0.2 µM 
filter.  
• Difco Mycobacteria 7H11 agar: 10.5 g 7H11 powder (Beckon and Dickinson, 
MD, USA) dissolved in 450 ml TDW with 5 ml 50% glycerol (Chem Supply, 
Gillman SA). The agar was autoclaved for 110 ⁰C for 15 min. After agar had 
cooled to 50-56°C, 100 ml of OADC enrichment was added, and poured into 
quadrant plates. Agar plates were stored at 4⁰C in the dark. 
• Middlebrook 7H9 broth: 2.35 g of 7H9 powder (Bacto, Liverpool, NSW) 
dissolved in 450 ml TDW with 2 ml 50% glycerol and 2 ml 10% Tween-20. 
The broth was autoclaved for 110 ⁰C for 15 min. After cooling to 50-56°C 100 
ml of ADC enrichment was added..  
 
	  
	  
23	  
	  
2.1.6 Antigens and cytokines for cell stimulation 
• Lipopolysaccharide (LPS) (Sigma): Cells were stimulated at a final 
concentration of 10 µg/ml. 
• Recombinant murine IFN-ɣ (R&D systems): Cells were stimulated at a final 
concentration of 100 U/ml. 
 
2.1.7 Antibodies and buffers for enzyme-linked immunosorbant assay 
(ELISA) 
• 1 % Bovine serum albumin (BSA)/ Tween-PBS (PBST): 5 g BSA dissolved 
in 500 ml PBST, and filter sterilized. 
• Substrate solution: 10 µl 30% H2O2, 1 ml 10X citrate buffer, 1 ml 10X ABTS 
mixed in 1 L TDW. 
• Blocking solution – 2 % BSA/PBST: 10 ml BSA mixed in 490 ml PBST. 
Table 2.1: List of antibodies used for ELISA 
Types of 
ELISA 
Primary Antibody (Ab) Secondary Antibody (Ab) 
Mouse TNF Mouse TNF Ab, Antigen 
Affinity-purified Polyclonal 
Goat IgG (R&D Systems, 
Minneapolis, MN) 
Mouse TNF-α Biotinylated Ab, 
Antigen Affinity-purified 
Polyclonal Goat IgG (R&D 
Systems) 
Mouse IL-12 In-house anti-mouse IL-12 Ab  
(List cell line (Centenary 
Institute)  
Biotin Rat Anti-Mouse IL-12 
(p40/p70) (BD Pharmingen, San 
Diego, CA) 
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2.1.8 Reagents used for RNA extraction and cDNA synthesis by 
reverse transcriptase polymerase chain reaction (RT-PCR) 
Table 2.2: List of reagents used for RNA extraction 
Techniques Reagents Company 
RNA isolation TRisure Bioline 
 Chloroform BDH 
 Isopropanol BDH 
 75 % ethanol (EtOH): 
100 % EtOH diluted in Ultra 
Pure distilled DNAse and 
RNAse free water 
Sigma-Aldrich 
 Ultra Pure DNAse and RNAse 
free water. Deionized, 
diethylpyrocarbonate (DEPC)-
treated water 
Invitrogen 
RNA precipitation glycogen (5 mg/ml) Bioline 
 Co-Precipitant Sodium 
Acetate 3 M, pH 5.5  
Ambion 
 100 % EtOH Sigma-Aldrich 
 
Reverse transcription of miRNA was carried out using the All-in-One miRNA first-
strand cDNA synthesis kit (GeneCopoeia, Rockville, MD, USA) according to the 
manufacturers instructions. 
Table 2.3: Components of All-in-One miRNA first-strand cDNA reagent kit   
Reagents Volume per 1 reaction 
2.5U/µl Poly A Polymerase 1 µl 
RTase Mix 1 µl 
5x PAP/RT Buffer 5 µl 
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Total RNA  200 ng* 
dd H2O (RNase and DNAse free) To make final volume of 25 µl 
* The total amount of RNA used in this study was 200 ng, which falls between the kit 
guidelines of between 1 ng – 5 µg. 
RNA quality and concentration was determined by NanoDrop 2000 
spectrophotometer (Thermo Scientific, Delaware, USA)  
 
2.1.9 Primers used for quantitative real-time polymerase chain 
reaction (RT-qPCR) of miRNA 
All primers for miRNA quantitation were purchased from GeneCopoeia (Rockville, 
MD, USA) and summarized in Table 2.4. 
Table 2.4: List of All-in-One miRNA qPCR primers  
Mature miRNA Precursor 
miRNA 
accession 
Mature sequence 
mmu-miR-29a-3p MI0000576 UAGCACCAUCUGAAAUCGGUUA 
mmu-miR-99b-3p MI0000147 CAAGCUCGUGUCUGUGGGUCCG 
mmu-miR-125a-3p MI0000151 ACAGGUGAGGUUCUUGGGAGCC 
mmu-miR-146a-5p MI0000170 UGAGAACUGAAUUCCAUGGGUU 
mmu-miR-155-5p MI0000177 UUAAUGCUAAUUGUGAUAGGGGU 
mmu-miR-221-3p MI0000709 AGCUACAUUGUCUGCUGGGUUUC 
RNU6  TGGCCCCTGCGCAAGGATG 
mmu-miR-let7a-1-3p MI0000556 CUAUACAAUCUACUGUCUUUCC 
 
2.1.10 Reagents used for quantitative real-time polymerase chain 
reaction (RT-qPCR) of miRNA 
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miRNA quantitation by real-time qPCR was carried out using the All-in-One miRNA 
qRT-PCR detection kit (GeneCopoeia, Rockville, MD, USA). 
Table 2.5: Components of All-in-One miRNA qRT-PCR detection kit  
Reagents Volume per reaction Final concentration 
2X All-in-One qPCR Mix 5 µl 1X 
All-in-One miRNA qPCR Primer 
(2 µM) 
1 µl 0.2 µM 
Universal Adaptor PCR Primer 
(2 µM) 
1 µl 0.2 µM 
First-strand cDNA (diluted 1:5) 1 µl  
ddH2O  2 µl  
Final Volume 10 µl  
 
2.1.11 Reagents for miRNA inhibitors and mimics transfection 
All reagents used for miRNA transfection are summarized in Table 2.6. 
Table 2.6: Summary of reagents used for miRNA transfection 
Reagents Company Notes 
miRCURY LNA microRNA 
Mimic hsa-miR-146a-5p 
 
 
 
EXIQON,Vedbaek, 
Denmark 
 
This oligonucleotide also 
targets mmu-miR-146a-5p 
in miRBase 
miRCURY LNA microRNA 
Mimic control cel-miR-39-3p 
 
miRCURY LNA Power 
Inhibitor hsa-miR-146a-5p 
 
miRCURY LNA Power 
Inhibitor Control 
 
Opti-MEM Reduced Serum Life Technologies, (+)L-glutamine, (+)HEPES, 
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Media Victoria, Australia and (+2.4 g/L Sodium 
Bicarbonate) 
HiPerFect Transfection 
Reagent 
QIAGEN, Victoria, 
Australia 
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2.2 Methods 
2.2.1 M. bovis BCG and M. tuberculosis  H37Rv infection 
M. bovis BCG and M. tuberculosis H37Rv bacterial stocks were stored at -80⁰C 
freezer in 30% (v/v) glycerol/PBS. To infect alveolar (AMJ2.C11) peritoneal (IC-21) 
macrophage cell lines, bacteria stocks were thawed and centrifuged at 6000 rpm for 
15 minutes to form a pellet. The supernatant was decanted and the pellet was 
resuspended in the supplemented Middlebrook 7H9 broth and cultured for several 
days at 37oC and measured daily by the spectrophotometer at an optical density (OD) 
600. Once the bacterial growth reached log phase the bacteria was centrifuged at 6000 
rpm for 15 minutes and resuspended in fresh antibiotic free media (RPMI or DMEM) 
at the required multiplicity of infection (MOI). One day prior to the infection, the 
macrophage cell lines were plated at a density of 5x105 cells/ ml in antibiotic free 
media in 24-well plates, unless otherwise stated. Cells were stimulated with 100U 
IFNɣ and incubated overnight. Bacteria were added to the cells at the required MOI, 
and incubated at 37⁰C and 5% CO2 for 4-6 hours before being washed with fresh 
media 3 times to remove extracellular bacteria. As the alveolar macrophage cell line 
grows in suspension, prior to washing, the cells were centrifuged at 1200 rpm for 2 
min at room temperature to pellet the cells onto the bottom of the plates. After 
infection, the cells were harvested at predetermined time points. 
2.2.2 Intracellular bacteria counts 
At predetermined time points, the supernatants of infected cells were removed and 
cells were lysed, to release intracellular bacteria, in 1 ml 0.1 % Triton-X 100 (Sigma) 
per well and incubation for 30 minutes at 37⁰C and 5% CO2. The lysate was serially 
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diluted 1:10 in TDW and 100 µl of the diluted lysate from different dilutions was 
plated onto four quadrants of 7H11 agar plates supplemented with OADC. The agar 
plates were incubated at 37⁰C and 5% CO2 for 15-21 days before colonies were 
counted. 
2.2.3 Tumour necrosis factor ELISA 
A 96-well ELISA plate was coated with polyclonal goat anti-mouse TNF Ab (0.8 
µg/ml) (R&D Systems) in PBS (100 µl/well) overnight at 4⁰C. The following day, the 
wells were washed 5-6 times with PBST, and this wash step was performed between 
all subsequent steps. The plate was then blocked with 1% BSA/PBS (200 µl/well) and 
incubated at room temperature for minimum of 1 hour. After blocking, serial 1:2 
dilutions of a TNF standard (highest standard: 4000pg/ml, R&D systems), samples 
and blank media were added into the designated wells and incubated for 2 hours at 
room temperature. The secondary biotinylated anti-mouse TNF antibody (0.4 µg/ml) 
in 1% BSA/PBS (100 µl/well) was added for 1 hour. The antibody was labelled by 
horse-radish peroxidase-labelled streptavidin in 1 % BSA/PBS (100 µl/well) for 1 
hour. During the incubation period, the substrate was prepared by adding 10X ABTS 
(Sigma) with 0.03% H2O2 and citrate buffer pH 4.5. After adding the substrate, the 
colour change was monitored, from clear to dark green. The absorbance of plate was 
measured at 405 nm with background subtracted at 492 nm using the MultiskanEX 
microplate reader (Thermo Labsystems). The absorbance of the samples was 
converted to the concentration (pg/ml) with the aid of the standards. The 
concentration of all standards and samples were calculated after excluding the 
background absorbance.  
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2.2.4 Interleukin-12 (IL-12p70) ELISA 
A 96-well ELISA plate was coated with an in-house anti-mouse IL-12 Ab (8 µg/ml) 
in carbonate buffer pH 9.1 (100 µl/well) for 1 hour at room temperature, or overnight 
at 4 ⁰C. Wells were washed 5-6 times with PBST the following day and this wash step 
was repeated between all subsequent steps. The plate was then blocked with 2 % 
FCS/PBS (200 µl/well) and incubated at room temperature for minimum of 1 hour. 
After blocking, serial 1:2 dilutions of IL-12 standard (highest standard: 10,000 pg/ml, 
BD Pharmingen, San Diego, CA), samples and blank media were added into the 
designated wells and incubated for 2 hours at room temperature. The secondary 
biotinylated rat anti-mouse IL-12 antibody (p40/p70) (BD Pharmingen, San Diego, 
CA) (1µg/ml) in 1 %BSA/PBS (100 µl/well) was added for 1 hour. The antibody was 
labelled by horse-radish peroxidase-labelled streptavidin in 1 % BSA/PBS (100 
µl/well) for 1 hour. ABTS substrate was prepared and added as described above 
(section 2.2.3), and colour change was monitored, from clear to dark green. 
Absorbance was measured at 405 nm with background subtraction at 492nm using 
MultiskanEX microplate reader (Thermo Labsystems). The absorbance of the samples 
was converted to concentration (pg/ml) with the aid of the standards and the 
concentration of all standards and samples.  
2.2.5 Nitrite and nitrate production test 
A set of NaNO2 standards was prepared in media ranging from 0-400 nmol/ml. To a 
U bottom 96-well plates; 50 µl of standards, blank media and collected supernatants 
were transferred and 50 µl of freshly prepared Greiss reagent added to each well. 
Greiss reagent was prepared by dissolving 0.1 % naphthylethylene diamine 
hydrochloride (Sigma), 1% sulphanilamide (Sigma), and 2.5 % phosphoric acid 
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(Sigma) in 50 ml triple distilled water (TDW). Colour change from clear to pink 
would appear immediately and was measured based on the absorbance level at a 
single wavelength of 540 nm on an MultiskanEX microplate reader (Thermo 
Labsystems). The quantified absorbance was converted to the concentration with the 
aid of the standards. The concentration of nitrite or nitrate was expressed in pmol/ml.  
2.2.6 RNA extraction  
Culture supernatants from all samples were collected and stored at -80oC for cytokine/ 
NO quantitation before harvesting the cells in 1 ml Trizol per well on 24-well plates at 
the indicated time points post infection.  Samples were quickly transferred into 
Eppendorf tubes and placed on dry ice to prevent RNA degradation. RNA samples 
were stored at -80 ⁰C. Samples were thawed at room temperature for 5 minutes, 200 
µl of chloroform added, samples shaken vigorously for 15 seconds and allowed to 
stand at room temperature for 5 minutes before centrifugation at 12000 rpm for 15 
minutes at 4 ⁰C. The upper aqueous phase layer (RNA containing layer) was collected 
into a new RNAse free 1.5 ml collection tube and 1 µl of glycogen (5 mg/ml) added. 
To precipitate RNA, 500 µl isopropanol was added and the samples were incubated at 
-20 ⁰C overnight. After the overnight precipitation, the samples were centrifuged at 
12000 rpm for 10 minutes at 4 ⁰C and supernatants  decanted. The RNA pellet was 
washed with 500 µl of 75 % molecular grade ethanol, vortexed and centrifuged at 
7500 rpm for 5 minutes at 4 ⁰C. The supernatant was discarded and the pellet air dried 
and redissolved in 25 µl of DEPC-treated Ultra Pure DNAse and RNAse free water. 
The RNA concentration and purity of RNA were determined by NanoDrop 2000 
Spectrophotometer (ThermoScientific, Delaware, USA). The concentration of RNA 
was measured based on the absorbance level at wavelength of260 nm and the purity 
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of RNA was determined based on the absorbance ratio at 260nm/280nm, with any 
ratio at 260 nm/280 nm ≥ 1.8 considered high quality RNA.  The absorbance at 
wavelength 230 nm detected contaminants which can interfere with the quantification 
of RNA samples. If the samples contained contaminants, overnight RNA re-
precipitation was required. Samples were stored at -80 ⁰C until use. 
2.2.7 Overnight RNA reprecipitation 
If NanoDrop 2000 Spectrophotometer detected any trace of contaminants including 
ethanol, the RNA samples were reprecipitated by the addition of 2.5 µl of 3 M sodium 
acetate (1/10 of the sample volume) and 50 µl of 100 % ethanol (200 % of the sample 
volume) before overnight incubation at -20 ⁰C. The next day the samples were 
centrifuged at 14000 rpm for 30 minutes at 4 ⁰C. The supernatant was discarded and 
the pellet was washed with 500 µl 75 % ethanol then centrifuged at 7500 rpm for 5 
minutes at 4 ⁰C. The ethanol was removed and the pellet was air dried for 10-20 
minutes and redissolved in 25 µl of DEPC-treated Ultra Pure DNAse and RNAse free 
water per sample. The concentration and purity of the RNA were determined by 
NanoDrop 2000 Spectrophotometer (ThermoScientific, Delaware, USA) and stored at 
-80 ⁰C. 
2.2.8 Reverse transcription of RNA 
Total RNA (200 ng) was reverse-transcribed by using All-in-One miRNA first-strand  
cDNA synthesis kit (GeneCopoeia, Rockville, MD, USA). RNA reverse transcription 
was prepared following the quantities listed on Table 2.3. The master mix was made 
with a total volume of 7 µl per sample that was added to 3 µl of the sample containing 
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200 ng RNA. The end volume of per sample was 10 µl. The samples were loaded into 
the thermal cycler with the following parameters set: 
Temperature Time 
37 ⁰C  60 minutes 
85 ⁰C  5 minutes 
4 ⁰C ∞ cooling down  
The resultant product was immediately stored at -20 ⁰C freezer.  
2.2.9  RNA quantification using Fragment Analyzer™ 
Other than Nanodrop 2000 spectrophotometer, this study also used Fragment 
Analyzer™  automated capillary electrophoresis (CE) (AATI, Ames, USA) which can 
provide a same standard of RNA reading as Bioanalyzer analysis. Quantification and 
qualification of RNA is performed silmutaneously. RNA assessment was carried out 
using Standard Sensitivity RNA Analysis Kit. The result of measurement includes 
RNA integrity number (RIN) and RNA concentration. 
 
RNA samples and RNA ladder were heat-denatured at 70⁰C. 22 µl of each sample and 
RNA ladder was transferred into RNase-free 96-well plate and mixed thoroughly with 
2 µl of RNA diluent marker. Intercelating dye mixed with RNA separation gel, 
conditioning buffer and inlet buffer were loaded into the Fragment Analyzer machine 
for setting up the instrument. After setting up the machine, the 96-well plate was 
ready to be loaded into the Fragment Analyzer machine and run with PROSize™ 
software versions 2.0 (AATI, Ames, USA) following manufacturer’s protocol. 
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Table 2.7: Summary of reagents used for RNA quantification using Fragment 
Analyzer 
Standard Sensitivity RNA Analysis kit component 
RNA separation gel 
Intercelating dye 
5X 930 dsDNA inlet buffer 
Standard sensitivity RNA ladder 
0.25X TE rinse buffer 
5X Capillary conditioning solution 
	  
	  
2.2.10 Quantitative real-time polymerase chain reaction (RT-qPCR) 
using SYBR green 
miRNA detection with real-time qPCR was carried out by using All-in-One miRNA 
RTq-PCR detection kit (GeneCopoeia, Rockville, MD, USA). The mastermix and 
cDNA sample were prepared following the volumes listed in Table 2.5. The end 
volume of per sample was 10 µl. RT-qPCR was performed on 7500 Fast Real-Time 
PCR System (Applied Biosystems) with 7500 Software (version 2.0.6) using a 
MicroAmp Fast Optical 96-well plate covered with Optical Adhesive Film (Applied 
Biosystems). The amplification cycle was set using the following parameters: 
Number of cycles Step Temperature Time 
1 Pre-denature 95 ⁰C 10 minutes 
40 Denature 95 ⁰C 10 seconds 
Annealing 60 ⁰C 20 seconds 
Extension 72 ⁰C 10 seconds 
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Melting analysis was completed after the amplification reactions to verify the 
amplification. RT-qPCR data was analysed using SDS Relative Quantification 
Software Version 2.3.  
2.2.11 Transfection of cells with miRNA-146a inhibitors, mimics or 
control 
Following the manufacturer’s protocol for HiPerfect transfection reagent (QIAGEN), 
cells were plated at a density of 2x105 cell per well in 100 µl antibiotic free RPMI or 
DMEM supplemented with 10 % FCS and incubated at 37 ⁰C and 5 % CO2,. 
Depending on the final concentration required for miRNA transfection, the volume of 
LNA miRNA inhibitor or mimic was adjusted and added into the mixture of 6 µl of 
HiPerfect transfection reagent and 100 µl serum-reduced Opti-MEM media per well. 
The mixture was vortexed briefly and incubated at room temperature for 10 minutes 
to allow the formation of transfection complexes. The transfection complexes were 
added drop-wise onto the cells to get uniform distribution of the complexes. The cells 
were incubated at 37 ⁰C and 5 %  CO2 for 6 hours before adding IFNɣ 100 U and free 
antibiotic 400 µl RPMI or DMEM supplemented with 10 % FCS. The cells were 
incubated overnight before the infection or analysis of gene silencing or 
overexpression. Prior to infection with M. tuberculosis, the media was removed and 
fresh antibiotic free media RPMI or DMEM supplemented with 10 % FCS was added 
at 1 ml per well. Cells were then infected as described in 2.2.1. 
2.2.12 Cytometric bead assay   
Cytometric bead assay (BD Biosciences, Sydney, Australia) uses multiple bead 
populations each bound to a different monoclonal antibody specific for one cytokine 
or chemokine to quantify several cytokines or chemokines simultaneously. 
	  
	  
36	  
	  
Interleukin-6, MIP-1α, MIP-1β, TNF, MCP-1 and RANTES were quantified in this 
study. 
A U-bottom 96-well plate was pre-wet with wash buffer before coating the plate 5 
µl/well with a mixture of six capture beads in the capture beads diluent. Every capture 
bead has a unique fluorescence intensity that is specific to each analyte. A set of 
standards ranging from 2500 pg/ml to 0 pg/ml was made with 1:2 serial dilutions. To 
the pre-coated 96 well plates, 5 µl of blank media or 5 µl of each standard dilution or 
5 µl of the supernatants were added. The plate was covered in foil and incubated for 1 
hour at room temperature. Without washing, a mixture of detection beads specific for 
each capture bead was added at 5 µl/well. The plate was covered in foil and incubated 
for another 1 hour at room temperature before adding 200 µl of wash buffer per well. 
The plate was centrifuged at 1800 rpm for 10 minutes, then the supernatants were 
removed carefully. Immediately, thereafter formalin was added at 120 µl per well for 
fixing the cells and killing any trace bacteria. The plate was covered with foil at all 
time. Following the manufacturer’s protocol, the LSR II Fortessa flow cytometer (BD 
Bioscience) was calibrated with the provided set-up beads. 300 events were required 
per analyte. Fluorescent intensity indicated the concentration of individual 
cytokine/chemokine. With the aid of the standard curve concentration, FCAP Array 
Software version 3.0 (BD Biosciences) the concentration (pg/ml) of each analyte was 
computed. 
2.2.13 Data Analysis 
All data are the mean of ± standard error of mean (SEM), unless otherwise specified. 
Statistical analysis of all data was computed using GraphPad Prism 6 (Graphpad 
Software Inc., San Diego, USA).  
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The relative expression of miRNA measured by RT-qPCR was calculated by the 2-
△△Ct method. The difference between multiple experimental groups was analysed by 
analysis of variance (ANOVA). The relationship between different experimental 
groups at a given time point was analysed by Student’s t-tests. The statistical 
significance was defined as p value <0.05. 
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3.1 Introduction 
M. tuberculosis is the causative agent of tuberculosis (TB) which predominantly 
infects pulmonary sites. M. tuberculosis is a slow-growing organism and has a 
complex cell wall rich in lipids. Its ability to survive despite the host defence response 
has been a challenge for decades to produce more effective treatments and protective 
vaccine. The only licensed vaccine against TB, Mycobacterium bovis Bacillus 
Calmette–Guérin or BCG, is an attenuated live bovine tuberculosis bacillus. BCG 
vaccine is strongly recommended for administration to all newborns in endemic areas 
to prevent TB meningitis and military TB (Tu et al., 2012). Unfortunately, the 
protective efficacy of BCG vaccine is highly variable between individuals and the 
protection of BCG wears off over time and revaccination does not enhance immunity 
(Tu et al., 2012). 
 
Alveolar macrophages are the predominant phagocyte to first encounter the tubercle 
bacilli. The uptake of the bacteria is mediated by complement receptors and mannose 
receptors (Flynn and Chan, 2001). Toll-like receptors (TLRs) also interact with 
components of the M. tuberculosis cell wall, activating a series of signal transduction 
pathways to release proinflammatory cytokines including TNF, IL-12, IL-8 and IL-1β 
(Flesch and Kaufmann, 1993). TNF and IFN-ɣ are the key cytokines, essential for the 
containment of the bacilli, aiding the formation of granulomas and activation of 
adaptive immunity. These proinflammatory cytokines enhance macrophage 
bactericidal activities including the induction of reactive oxygen species and nitrogen 
oxides (MacMicking et al., 1997).  
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One of the reasons TB is difficult to diagnose is due to its latency in the host. Most 
individuals who are infected with M. tuberculosis contain the infection in a latent state 
and carry only a 5% lifetime-risk of reactivation of TB disease, except for 
immunocompromised individuals who are not able to contain the bacilli. M. 
tuberculosis employs multiple strategies to avoid destruction while residing within 
macrophages (McDonough et al., 1993). Interestingly, the granuloma formed by 
activated alveolar macrophages as well as other inflammatory cells restricts the 
growth of M. tuberculosis, but also serves a niche for the bacteria to remain dormant 
and proliferate if immunity is compromised. Taken together, the host possesses a 
complex defence system to fight tubercle bacilli, but the bacteria itself also has a set 
of strategies to evade the host immune response.  
 
There is growing evidence that miRNAs are involved in cellular development, 
proliferation and differentiation (Ambros, 2004). miRNAs are small non-coding RNA 
molecules, 21-25 nucleotides in length (Bartel, 2004). miRNAs regulate their target 
genes at the post-transcriptional level by binding to the 3’ untranslated region (UTR) 
of messenger RNA (mRNA). The importance of miRNAs in many biological 
processes has been highlighted by studies demonstrating a correlation between 
dysregulation of miRNAs and a wide spectrum of diseases including cancer, 
autoimmunity, cardiac diseases and others (Knezevic et al., 2015, Krenning et al., 
2010, Kloosterman and Plasterk, 2006). In immunity, some miRNAs have been found 
to be negative regulators acting to control the production of cytokines. Alterations in 
miRNA expression profiles have been detected in peripheral blood-derived 
macrophages, serum plasma and sputum from patients with M. tuberculosis (Das et 
al., 2013, Fu et al., 2011). However, whether these alterations in miRNAs induced by 
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M. tuberculosis infection modulates the production of proinflammatory cytokines and 
the overall induction of a protective immune response remains unknown. 
 
Recent studies have demonstrated the upregulation of certain miRNAs by M. 
tuberculosis infection in murine macrophages (RAW264.7) and human-monocytic 
(THP-1) cells (Das et al., 2013, Liu et al., 2014b, Rajaram et al., 2011, Wang et al., 
2014). However, little is known regarding the response of murine alveolar 
macrophage (AMJ2.C11) and peritoneal macrophage (IC-21) cell lines against the M. 
bovis BCG vaccine strain or the virulent M. tuberculosis H37Rv strain. Therefore, this 
study selected a set of miRNAs, reported to be expressed by macrophages and studied 
their differential expression during Mycobacterium infection. The expression of these 
miRNAs was examined to determine if the virulence of the mycobacterial strain, and 
the origin of the infected macrophage influenced the expression of selected miRNAs.
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3.2 Results 
3.2.1 M. bovis BCG infection in macrophages  
Alveolar (AMJ2.C11) and peritoneal (IC-21) macrophages were infected with BCG 
and nitric oxide and TNF production assessed at 6 and 24 hours post infection. Both 
macrophage cell lines produced a significant amount of nitric oxide by 24 hours 
following M. bovis BCG infection, while at 6 hours the amount of nitric oxide 
produced was below the limit of detection (5 nmol/ml) (Figure 3.1.A and 3.1.B). In 
contrast, the production of TNF peaked at 6 hours with levels decreasing by 24 hours 
(Figure 3.1.C and 3.1.D). Infected AMJ2.C11 cells produced more TNF than IC-21 
cells. Higher infectious dose of BCG infection led to more nitric oxide and TNF 
release by both types of macrophages. 
 
IL-12 is one of the proinflammatory cytokines is produced by human alveolar 
macrophages after the inhalation of M. tuberculosis. In this study, one experiment 
showed IL-12 was induced by BCG infection at a 5:1 MOI but the level of IL-12 was 
below the limit of detection (312 pg/ml) when the infection was at a 1:1 ratio (Figure 
3.1F and 3.1G). However, 2 other repeated experiments demonstrated that regardless 
of the dose of BCG infection, neither AMJ2.C11 cells nor IC-21 cells produced a 
detectable amount of IL-12. This finding shows that minimal IL-12 was produced by 
either AMJ2.C11 and IC-21 cells in response to BCG infection. 
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The relative expression of miRNAs in this study was measured by RT-qPCR and 
calculated using the 2(-△△Ct) method. The formula of 2(-△△Ct) is show in Figure 3.2. The 
ideal reference genes act as an endogenous control of miRNA due to consistent 
expression levels irrespective of the treatment to the cells. Reference genes are 
necessary to normalize any variations in samples, measurements and examinations 
(Wotschofsky et al., 2011). Small nuclear RNA, RNU6, is a widely used reference 
gene for miRNA studies in cell and tissue samples. Interestingly, this study found that 
the expression of U6 (Figure 3.3A) was inconsistently expressed in all samples. In 
contrast, Let-7a expression was stable in all samples regardless of BCG infection 
(Figure 3.3B). Let-7a was also consistently expressed in other repeated experiments; 
hence, this study used Let-7a as reference gene instead of RNU6. 
 
Figure 3.4 showed the differential expression of 6 selected miRNAs in alveolar 
macrophage (AMJ2.C11) following M. bovis BCG infection MOI 1. Clearly, miR-
146a and miR-155 were very responsive to BCG infection marked by a high fold 
change and a significant upregulation by 24 hours. The upregulation of miR-146a was 
10 fold higher than uninfected cells, whereas miR-155 was 100 fold more upregulated 
than uninfected cells. miR-29, miR-99b and miR-221 showed a trend towards 
upregulation by 6 hours. While one experiment showed miR-99b was upregulated at 
24 hours, repeated experiment showed the expression levels of miR-99b and miR-221 
returned to the level seen in uninfected cells by 24 hours, while miR-29a was 
downregulated by 24 hours. In contrast, miR-125a was downregulated by 6 hours 
with the expression level remaining low by 24 hours. 
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Similar to the response seen in the AMJ2.C11 cells, miR-146a and miR-155 were 
significantly upregulated in the IC-21 peritoneal macrophage cell line following M. 
bovis BCG infection at an MOI 1:1. These 2 miRNAs were significant upregulated by 
6 hours and remained so at 24 hours (Figure 3.5). Expression of miR-221 followed a 
similar pattern and was also significantly elevated by 6 hours with the level remaining 
upregulated at 24 hours. Interestingly, IC-21 cells had a different expression profile of 
miR-29a and miR-125a compared to AMJ2.C11 cells. In IC-21 cells, miR-29a and 
miR-125a had a trend towards upregulation by 24 hours, and miR-99b was 
significantly upregulated by 24 hours. In AMJ2.C11 cells, miR-29a and miR-125a 
had a pattern of downregulation (Figure 3.4). 
3.2.2. M. tuberculosis infection in macrophages  
After seeing the changes in miRNA expression in the cells following M. bovis BCG 
infection, cells were next infected with virulent M. tuberculosis H37Rv at a 1:1 and a 
5:1 MOI. In response to M. tuberculosis infection, expression of all 6 miRNAs was 
significantly upregulated in both AMJ2.C11 and IC-21 cells (Figure 3.6 and 3.8). In 
these two cell lines, miR-146a and miR-155 were the most upregulated miRNAs in 
response to M. tuberculosis infection. 
 
In AMJ2.C11 cells, unlike the miRNA expression profile induced by BCG infection, 
cells infected with M. tuberculosis did not show downregulation of miR-29a and miR-
125a at 24 hours post infection (Figure 3.6). In contrast, M. tuberculosis induced 
significant upregulation of miR-29a and miR-125a by 24 hours. The trend of early 
expression of miR-221 induced by BCG infection was also not seen in M. 
tuberculosis infection. miR-221 was upregulated significantly by 24 hours with 
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infection at MOI 5 (Figure 3.6). These data indicate that M. tuberculosis infection in 
AMJ2.C11 cells induces a different miRNA expression pattern compared to M. bovis 
BCG (Figure 3.7). Interestingly though, despite some changes in the expression 
patterns of the miRNA between the two infection models infected with M. 
tuberculosis, the level of increase in miRNA expression was relatively similar 
between M. tuberculosis and BCG at the same MOI (Figure 3.7). 
 
Although the 6 selected miRNAs in this study were all upregulated significantly in 
AMJ2.C11 and IC-21 following M. tuberculosis infection, infected IC-21 cells 
expressed a different pattern of miRNAs expression to that seen in the AMJ2.C11 
cells. All analysed miRNAs were significantly upregulated by 6 hours post infection 
(Figure 3.8A and 3.8B) with the expression level returning nearly to the baseline by 
24 hours except for miR-146a and miR-155. Expression of both miR-146a and miR-
155 were significantly reduced by 24 hours compared to the 6 hour peak but the level 
remained upregulated compared to uninfected cells. In this cell line, virulent M. 
tuberculosis did induce a different miRNAs expression profile compared with M. 
bovis infection (Figure 3.9). Only miR-221 was expressed in the same fashion 
regardless of the strain of Mycobacterium infection.  
 
In AMJ2.C11 and IC-21 cells, even with a low dose infection of 0.1:1 MOI, miR-146 
and miR-155a were upregulated, and increasing the infectious dose did not 
necessarily lead to  further increases in expression of these miRNAs. 
 
	  
	  
46	  
	  
Based on the findings that AMJ2.C11 showed marked  upregulation of miRNAs at 24 
hours while IC-21 had an early upregulation of miRNAs by 6 hours, this study further 
examined the expression patterns of these  miRNAs at different time points. 
Interestingly, in the AMJ2.C11 cells the sustained increase in miRNA expression 
continued with these miRNAs remaining significantly upregulated after 48 hours 
infection (Figure 3.10A), whereas in the IC-21 cells several of the miRNAs; miR-29a, 
-125a, -146a and -155 were already upregulated by 2 hours post infection with levels 
of all miRNAs measured peaking between 2-6 hours post infection (Figure 3.10B). 
Given the differences in the miRNA profile, this study next examined if the 
production of a range of the cytokines/chemokines by AMJ2.C11 and IC-21 cells also 
differed following M. tuberculosis infection. 
 
M. tuberculosis induced the production of TNF by both AMJ2.C11 cells (Figure 
3.11A and 3.11B) and IC-21 cells (Figure 3.11C and 3.11D). TNF was produced by 6 
hours and levels remained significantly elevated at later time points. The amount of 
TNF produced by AMJ2.C11 and IC-21 cells were relatively similar.  
 
Uninfected AMJ2.C11 and IC-21 cells produced a low level of RANTES. Upon 
infection both AMJ2.C11 (Figure 3.12A and 3.12B) and IC-21 cells (Figure 3.12C 
and 3.12D) produced significantly more RANTES by 6 hours with the level remaining 
elevated at 24 and 48 hours. When infected with a higher dose of M. tuberculosis, the 
amount of RANTES produced by IC-21 did not increase further (Figure 3.12D). In 
contrast, the higher dose of M. tuberculosis infection induced more RANTES from 
the AMJ2.C11 cells (Figure 3.11B). 
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The production of MIP-1α and MIP-1β was also measured in the supernatants. It was 
found that MIP-1α and MIP-1β were constitutively produced by both the AMJ2.C11 
(Figure 3.13A, B, E and F, respectively) and IC-21 cells (Figure 3.13C, D, G and H, 
respectively). Interestingly, M. tuberculosis infection did not increase the production 
of either of these two chemokines, indeed a reduction in the levels of MIP-1α and 
MIP-1β during the course of infection was noted in both cell lines, suggesting that the 
infection might inhibit the cells release of MIP-1α and MIP-1β, or that these 
chemokines were being utilised by other cells within the well.  
 
Monocytic chemotactic protein-1 (MCP-1) was also induced by M. tuberculosis 
infection in AMJ2.C11 (Figure 3.14A and B) and IC-21 cells (Figure 3.14C and D). 
Increased MCP-1 was detected by 6 hours and levels remained significantly 
upregulated at 48 hours. Although Figure 3.14B showed a reduction of MCP-1 level 
by 48 hours following M. tuberculosis infection at 5:1 MOI, repeated studies showed 
elevated MCP-1 at 48 hours. Interestingly, uninfected AMJ2.C11 and IC-21 cells 
themselves constitutively release MCP-1 (Figure 3.13A and C). Unlike MIP-1α and 
MIP-1β data, M. tuberculosis infection did lead to an increase in the production of 
MCP-1. 
 
Finally the relationship between the intracellular growth of M. tuberculosis, and 
miRNA expression and cytokine/chemokine expression was examined. The higher 
infection dose lead to ~50% increase in the amount of bacteria taken up by the cells 
by 6 hours (Figure 3.15). The bacteria load in AMJ2.C11 cells did not change 
significantly between 6 hours and 24 hours. However, bacterial growth was 
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significantly reduced by 48 hours (Figure 3.15A). Even with a higher dose of 
infection, significant bacterial killing was only seen by 48 hours (Figure 3.15B). IC-
21 cells showed less uptake of M. tuberculosis compared with AMJ2.C11 at 6 hours 
(Figure 3.16A and B), and M. tuberculosis load significantly increased in the IC-21 
cells by 24 hours (Figure 3.15C, D and 3.16B) regardless the dose of infection. Figure 
3.15C and 3.15D which showed less bacterial uptake by the IC-21 cells compared 
with AMJ2.C11 cells at 6 hours was due to the effect of freezing the bacterial plates 
before replating the bacteria. The freeze thawing of the bacteria in water causes a 
known reduction in bacterial viability.  
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3.3 Discussion 
This study revealed that M. bovis BCG infection and M. tuberculosis infection induce 
different miRNAs expression profiles. Furthermore, my findings demonstrated that 
AMJ2.C11 and IC-21 cells, despite both macrophage cell lines being derived from 
C57BL/6 mice, they induce different miRNAs expression profiles particularly when 
infected with virulent M. tuberculosis.  
 
To examine the effect of M. tuberculosis on miRNA expression, this study selected 
six microRNAs that have been reported to be regulated in the host in response to 
Mycobacterium infection (Li et al., 2013, Ma et al., 2011a, Rajaram et al., 2011, 
Sharbati et al., 2011, Wang et al., 2014, Singh et al., 2013). This study was interested 
in the response of the AMJ2.C11 and IC-21 macrophages for a number of reasons. To 
date, there have not been any published studies examining the miRNAs expression 
profile of the alveolar macrophage (AMJ2.C11) and peritoneal macrophage (IC-21) 
cell lines. These lines are of interest as they are both derived from C57BL/6 mice, 
which are the primary mouse strain used for mouse studies following M. tuberculosis 
infection. Most of the knockout strains of mice used in M. tuberculosis studies are 
also on a C57BL/6 background so these cell lines provide a first line of investigation 
as to their response to infection.  
 
Alveolar macrophages are essential to control M. tuberculosis infection. Interestingly, 
in part due to difficulties in isolating lung macrophages, relatively little is known 
regarding how they respond to infection and if this varies from other resident 
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macrophages, such as blood derived or peritoneal. The AMJ2.C11 cell line provides 
an excellent place to start to examine the response of lung derived macrophages to M. 
tuberculosis infection and they were our major interest in this study. This study 
included IC-21 cells so that a comparison between pulmonary derived and extra 
pulmonary macrophages in the response to infection could be examined. Examining 
miRNAs expression profile in these two murine cell lines following Mycobacterium 
infection provides a good baseline comparison for future studies on miRNAs 
expression profiles in primary murine macrophages and complements current on-
going research in our group on human macrophages. These studies help to provide a 
more robust understanding of the miRNA expression profile of macrophages and how 
it is influenced by the strain of mycobacterium and the source of macrophages. 
 
Despite the different pattern of miRNAs expression between AMJ2.C11 and IC-21 
cells, both types of cells displayed a similar proinflammatory cytokines/chemokines 
profile when challenged with either M. bovis or M. tuberculosis. Mycobacterial 
infection induced a significant amount of TNF and nitric oxide. M. tuberculosis 
induced the production of RANTES and MCP-1 but not MIP-1α and MIP-1β. 
Interestingly, despite having a similar proinflammatory cytokines/chemokines profile, 
AMJ2.C11 cells showed better intracellular bacterial killing compared with IC-21 
cells. This may be influenced by the different pattern of miRNA expression seen, 
leading to activation of additional, as yet undetermined, bactericidal mechanisms. 
 
Following BCG infection, both AMJ2.C11 and IC-21 cells produced significant 
amounts of nitric oxide and TNF. Clearly, the infection induced nitric oxide and TNF 
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release as uninfected cells did not produce either NO or TNF (Figure 3.1A-D). 
AMJ2.C11 and IC-21 cells released TNF earlier than nitric oxide. Significant TNF 
was already released by 6 hours, whereas nitric oxide release was not significantly 
increased until 24 hours post infection. It is well documented that TNF and IFN-ɣ 
activate macrophages enhancing their bactericidal activity by the induction of nitric 
oxide via nitrogen oxide synthase (NOS2) (MacMicking et al., 1997). Therefore, TNF 
production by AMJ2.C11 and IC-21 cells might be necessary for activating the 
macrophages to produce nitric oxide. 
 
IL-12, produced by macrophages and dendritic cells is one of the host responses to 
infection which is essential for the activation of acquired protective immunity 
necessary to clear intracellular infections (Skeen et al., 1996). Skeen et al. reported 
that murine bone marrow-derived macrophages produced IL-12 following M. bovis 
BCG infection. The production of IL-12 was enhanced in cells primed with IFN-ɣ. 
Neither M. bovis or schistosome infection induced the production of IL-12 in mutant 
mice that lacked the IFN-ɣ receptor. Furthermore, numerous studies have 
demonstrated that IFN-ɣ primed macrophages show enhanced killing activity against 
M. tuberculosis (Dorman and Holland, 1998, Denis, 1991, Herbst et al., 2011). 
Therefore, in this study both macrophage cell lines were primed overnight with IFN-ɣ 
prior to M. tuberculosis infection. However, despite the IFN-ɣ priming AMJ2.C11 
and IC-21 cells produced only a minimal amount of IL-12, often below the limit of 
accurate detection (312 pg/ml) following M. bovis BCG infection with an MOI of 1 
(Figure 3.1E and 3.1F, respectively). Although more IL-12 was induced by the higher 
dose of infection, BCG infection at an MOI of 5 still only induced minimal IL-12. 
This study also challenged both types of macrophages with LPS 500 ng and IFN-ɣ 
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100U and surprisingly found that neither AMJ2.C11 nor IC-21 cells produced 
significant amount of IL-12. The ELISA was optimized to increase the limit of 
detection, but again the optimization did not change my findings, that neither 
AMJ2.C11 nor IC-21 cells produce significant IL-12 following mycobacterial 
infection or LPS stimulation.  
 
This ELISA measured IL-12p70, the mature form of IL-12. The IL-12p40 chain also 
binds with p19 to form IL-23. Studies have suggested that macrophages may make 
more IL-23 while dendritic cells make more IL-12 (Cooper and Khader, 2008). Future 
studies could measure the amount of IL-23 produced by these cell lines to determine 
if they are making this alternative cytokine. Little is known regarding the cytokines 
production profile of these two types of macrophages. Despite the low production of 
IL-12, AMJ2.C11 cells still reduced intracellular growth by 48 hours after M. 
tuberculosis infection. 
 
To study miRNAs expression profile, a reference miR is essential to normalize any 
variations caused by sampling, experiments and measurements. Small nuclear RNA 
(snRNA) RNU6B has been widely used as a reference in tissue and cell studies (Tili 
et al., 2007, Wang et al., 2014, Wang et al., 2013). However, a recently published 
study by our group found that RNU6B was not stably expressed in the plasma, despite 
its use as a reference in other studies (Timoneda et al., 2012, Schaefer et al., 2010, 
Huang et al., 2010, Barry et al., 2015).  Our early studies also showed that RNU6B 
was not stably expressed in our cells. When RNA levels were measured using the 
Fragment Analyzer and then equivalent amounts of RNA added to produce cDNA it 
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was found that the expression of Let-7a was more stable than U6 snRNA (Figure 3.3). 
Initially there was a hesitation to use Let-7a as reference gene in this study as some 
studies have reported changes in Let-7a expression in cancer models and some 
infections (Roush and Slack, 2008). Let-7 family, the first miRNA found in C. 
elegans by Ambros et al., are highly conserved across species and studies suggest 
dysregulation of members of the let-7 family might lead to tumour formation (Roush 
and Slack, 2008, Ambros, 2004, Chiu et al., 2014). In response to bacterial pathogens, 
some papers have indicated that Let-7 expression may be modulated, depending upon 
the cell type examined. Izar et al (Izar et al., 2012) demonstrated that Listeria 
monocytogenes infection downregulated Let-7a on CaCo-2 cells, Schulte et al 
(Schulte et al., 2011) reported the dowregulation of Let-7 family induced by 
Salmonella enterica infection on HeLa cells and murine macrophage RAW 264.7 
cells. However, other studies have used Let-7 as a reference gene (Chen et al., 2013, 
Mattie et al., 2006). Therefore, after analysis of the expression profiles of the miRNAs 
and testing for the most suitable normalisation miRNA, it was determined that instead 
of using U6 snRNA, it was more accurate to use Let-7a for normalization.  
 
This study examined the expression of 6 miRNAs, chosen because they are expressed 
by macrophages and had been shown to be upregulated in the plasma of M. 
tuberculosis infected patients versus healthy controls (Barry et al. personnel 
communication). The study aimed to determine if miRNA expression levels correlated 
with the levels of the proinflammatory cytokine TNF or other chemokines associated 
with inflammation during M. tuberculosis infection. These data show that both IC-21 
and AMJ2.C11 cells produced TNF within 6 hours of M. tuberculosis infection. 
Levels of TNF produced were similar between the two strains despite differences in 
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the pattern of miRNAs expression seen. These data suggest that either expression of 
specific miRNAs alone was insufficient to influence the pattern of the measured 
cytokines or chemokines released from the infected macrophages, or that the 
combined expression patterns of multiple miRNAs led to the changes in the 
proinflammatory response of the cells. These observations require further 
investigation as other studies have reported a correlation between expression of a 
specific miRNA and TNF levels, including miR-146a and miR-125, both of which 
were examined in this study (Liu et al., 2014a, Tili et al., 2007).  
 
Expression of miR-29 was downregulated in AMJ2.C11 macrophages infected with M. 
bovis BCG (Figure 3.7), but was upregulated by M. tuberculosis infection. In IC-21 
macrophages, infection with either mycobacterial strain led to an increase in miR-29 
expression at 6 hrs, with levels returning to normal by 24 hrs (Figure 3.9). 
Interestingly, a paper by Ma et al demonstrated that M. bovis BCG or L. 
monocytogenes infection of mice down-regulated miR-29 in CD4 and CD8 T cells 
and that miR-29 directly targeted IFNɣ mRNA (Ma et al., 2011a). Furthermore, the 
authors developed transgenic mice which outcompeted the host for miR-29; these 
miR-29-deficient mice were more resistant to Listeria infection, with reduced 
bacterial burden and higher TNF mRNA. In this study we did not find a correlation 
between miR-29 expression and TNF release by either of the infected macrophage 
cell lines. This may be because miR-29 is targeting T cells and natural killer cells and 
not macrophages. The finding of Ma et al suggested that the increased expression of 
miR-29 during the course of infection might actually enhance mycobacterial growth, 
further work inhibiting miR-29 expression in macrophages during M. tuberculosis 
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infection is required to determine if miR-29 can modulate M. tuberculosis growth in 
macrophages directly. 
 
These studies also found that miR-99b expression was upregulated in both IC-21 and 
AMJ2.C11 cells infected with M. tuberculosis. In IC-21 cells the upregulation peaked 
at 6 hrs, while in AMJ2.C11 cells levels peaked at 24 hrs. In a study by Singh et al, 
miR-99b was shown to target TNF in murine dendritic cells (Singh et al., 2013). 
Silencing miR-99b increased the production of TNF, IL-6, IL-12 and IL-1β, leading 
to a reduction in intracellular M. tuberculosis growth. My findings showed that the 
expression of miR-99b in AMJ2.C11 and IC-21 macrophages was similar to that seen 
in murine dendritic cells and it would be interesting to determine if silencing miR-99b 
in macrophages was an effective way to reduce mycobacterial growth both in vitro 
and in vivo. If silencing miR-99b in vivo also leads to increased production of 
proinflammatory cytokines like TNF this may cause problems with excessive 
inflammation in the host as this balance needs to be tightly regulated. 
 
In studies by Rajaram et al (Rajaram et al., 2011) M. tuberculosis infection increased 
the expression of miR-125b in human macrophages, while infection with an avirulent 
strain of Mycobacterium downregulated miR-125b. miR-125b targets the 3’UTR of 
TNF mRNA transcript, leading to the degradation and downregulation of TNF. My 
studies found an increase in miR-125a expression during M. tuberculosis infection in 
the two infection models, while M. bovis BCG downregulated miR-125a in 
AMJ2.C11 cells. Although little is known regarding miR-125a expression after 
Mycobacterium infection, this study showed that the expression profile of miR-125a 
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in AMJ2.C11 was similar to that of miR-125b in the study done by Rajaram et al. 
miR-125a and miR-125b reportedly have the same target sites so increased miR-125a 
may be expected to lead to a degradation of TNF. This was not seen in this study. 
TNF expression is reportedly regulated by multiple miRNAs, including miR-155 and 
this balance between miR-125 and miR-155 may be critical for controlling TNF 
expression. 
 
miR-155 is one of the most studied multifunctional microRNA in inflammatory and 
immune responses (Tsitsiou and Lindsay, 2009, O'Connell et al., 2007, Tili et al., 
2007, Wang et al., 2013, Yang et al., 2015, Ghorpade et al., 2012). A few studies have 
shown that the expression profile of miR-155 is variable following mycobacterial 
infection. Das et al found that M. tuberculosis infection of PBMCs-derived 
macrophages downregulated miR-155, while infection of murine bone marrow-
derived macrophages upregulated miR-155 (Das et al., 2013). Rajaram et al reported 
that avirulent M. smegmatis induced the upregulation of miR-155 in human 
macrophages, while M. tuberculosis induced the downregulation of miR-155 
(Rajaram et al., 2011). In this study, both M. bovis BCG and M. tuberculosis infection 
led to significant upregulation of miR-155 in AMJ2.C11 and IC-21 cells.  
 
As miR-155 is multifunctional in immunity, studies have demonstrated both the pro-
inflammatory and inhibitory rolea of miR-155 in response to mycobacterial infection. 
Wang J et al demonstrated that M. bovis BCG infection upregulated miR-155 in 
murine macrophage RAW 264.7 (Wang et al., 2014). This upregulation was 
dependent on TLR2, NF-κB and JNK signaling pathways. The upregulated miR-155 
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also enhanced reactive oxygen species (ROS) by repressing src homology2 containing 
inositol 5-phosphatase (SHIP1), a negative regulator of phosphatidylinositol 3-kinase 
(PI3K) and the serine/threonine kinase AKT pathway. Although how SHIP-1 
modulates ROS is not clear. Wang J et al showed that suppressing SHIP-1 increased 
the level of ROS in BCG-infected cells. Overall, the expression of miR-155 induced 
by BCG enhanced ROS production in macrophage, which promoted better bacterial 
containment. Rajaram et al reported that M. smegmatis infection induced a high miR-
155 level, which enhanced TNF production by downregulating SHIP-1, a negative 
regulator of TNF production (Rajaram et al., 2011). In contrast, Kumar et al showed 
that miR-155 induced by M. tuberculosis infection also repressed SHIP-1, but this 
favoured AKT activation, which is required for mycobacterial survival in 
macrophages(Kumar et al., 2012). They also found miR-155 inhibited the production 
another proinflammatory cytokine, IL-6. The suppression of SHIP-1 by miR-155 is 
like a tipping scale with two apparently contradictory outcomes, either favouring 
AKT activation or increasing TNF production. Indeed, miR-155 exerts other 
regulatory functions that influence the final outcome following mycobacterial 
infection and further work is required to fully elucidate the functions of miR-155. 
 
Current data suggests that miR-155 is differentially expressed in human macrophages, 
where infection with avirulent Mycobacterium enhances miR-155 expression whereas 
infection with virulent M. tuberculosis downregulates miR-155 expression. In contrast, 
infection with either virulent or avirulent Mycobacterium strains upregulates miR-155 
expression in murine macrophages. The differences in the response of human and 
murine macrophages need further studies to comprehensively define the role of miR-
155 in macrophages derived from different species. 
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In this study miR-221 was upregulated early at 6 hours post BCG infection, in both 
AMJ2.C11 and IC-21 cells with miR-221 level returning to the baseline by 24 hours. 
A similar pattern of expression was seen in IC-21 cells infected with M. tuberculosis, 
where miR-221 levels peaked at 6 hours post infection and had returned to baseline by 
24hrs. In AMJ2.C11 cells, miR-221 levels were not raised at 6 hours but had 
increased significantly by 24 hours (Figure 3.6B) remaining elevated at 48 hours post 
infection (Figure 3.10). This result is consistent with the result of ongoing studies in 
our research group on peripheral blood–derived human macrophages which showed 
that miR-221 was upregulated after M. tuberculosis infection at 24 hours post 
infection (Barry S. et al., personnel communication unpublished observations). What 
role that miR-221 is playing in immunity to mycobacterial infections is currently not 
known and certainly requires further investigation. 
 
Along with miR-155, miR-146a was one of the most upregulated miRNAs in both 
AMJ2.C11 and IC-21 cells following M. bovis BCG or M. tuberculosis infection. 
miR-146a has been shown to target TLR-dependent NF-κB signalling pathway 
(Taganov et al., 2006), leading to the  downregulation of IRAK-1 and TRAF-6, key 
molecules of the signalling pathway, resulting in the inhibition of proinflammatory 
cytokines release. Also, silencing miR-146a in alveolar A549 epithelial cells, which 
were then stimulated with a high concentration of IL-1β, negatively regulated IL-8 
and RANTES expression, while overexpression of miR-146a enhanced IL-8 and 
RANTES. These data suggest that overexpression of miR-146a under a strong 
inflammatory stimuli may function as a negative feedback mechanism to control the 
inflammation (Perry et al., 2008). Liu et al examined miR-146a expression by human 
monocytic (THP-1) cells in response to M. bovis BCG infection and showed that miR-
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146a was upregulated following infection. Our findings also demonstrated the 
upregulation of miR-146a in AMJ2.C11 and IC-21 cell following either BCG or 
virulent M. tuberculosis infection. In addition, M. tuberculosis also induced miR-146a 
in human monocyte-derived macrophages (Barry S. et al., personnel communication 
unpublished data); however, miR-146a was downregulated in the serum and sputum 
from patients with tuberculosis (Liu et al., 2014a). The reason for the different 
expression of miR-146a between serum-based and cell-based studies is not known but 
maybe the long chronic course of tuberculosis infection might alter the expression of 
miR-146a over time, or miR-146a expressed by macrophages may not be released by 
these cells. Also, the downregulation of miR-146a seen in patients’ sputum and serum 
may be necessary to enhance the inflammatory response in order to recruit sufficient 
inflammatory cells to contain the bacterial infection. Studies examining the role of 
miR-146a in mice during M. tuberculosis infection may help to clarify the similarities 
and differences in the response of humans and mice, both in vivo and in vitro in regard 
to miRNA expression following mycobacterial infection and the function of 
individual miRNAs. The role of miR-146 in the macrophage response to M. 
tuberculosis infection will be further examined in Chapter 4. 
 
One of the strongest differences seen in this experiment was the different miRNA 
expression pattern seen in the IC-21 cells compared to the AMJ2.C11 cells. Of the 6 
selected miRNAs were all upregulated by 6 hours in the IC-21 cells, with miR-29a, -
125a, -146a and -155 peaking within 2 hours of M. tuberculosis infection and the 
levels of all 6 had decreased nearly to baseline by 24 hours, except for miR-146a and 
miR-155. It is possible, as these two were the most upregulated miRNAs in this study, 
they required a longer time to return to baseline, or it could be that as the infection is 
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increasing in the IC-21 cells that this continues to stimulate expression of these miRs 
but not the others. These data clearly show that there are differences in the miRNA 
expression patterns based on both the cell line infected and the virulence of the 
infective strain. This was most apparent in comparing the response of AMJ2.C11 cells 
to BCG or M. tuberculosis. M. bovis BCG, the less virulent strain of mycobacteria, 
induce a pattern of downregulation of mir-29a and miR-125a, while M. tuberculosis 
increased the overexpression of miR-29a and miR-125a.  
 
When comparing the response of IC-21 cells to BCG or M. tuberculosis, we also 
found that despite the upregulation of all miRNAs after BCG challenge, the response 
to M. tuberculosis infection was more uniform, with all of the selected miRNAs 
upregulated by 6 hours decreasing nearly to baseline by 24 hours. In summary, 
alveolar and peritoneal macrophages had markedly different patterns of miRNAs in 
response to M. BCG and M. tuberculosis infection. Also, our findings indicated that 
the virulence of the Mycobacterium, BCG is much less virulent than M. tuberculosis, 
had an impact on miRNAs, inducing a different miRNAs expression pattern in each 
infection model. It would be interesting in future studies to determine if primary 
murine alveolar and peritoneal macrophages also have a different miRNAs response 
towards two strains of mycobacterial infection and thus how representative of the 
primary response the response in these cell lines are. 
 
Upon M. tuberculosis infection, macrophages are activated and release an array of 
proinflammatory cytokines including such as TNF-α, IL-12, IL-8 and IL-1β. At the 
same time, these activated macrophages also release a range of chemokines including 
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RANTES, MCP-1, MIP-1α and MIP-β to recruit other circulating inflammatory cells 
to form the granuloma in the lung. Hence, this study examined the cytokines and 
chemokines profile of AMJ2.C11 and IC-21 cells following M. tuberculosis infection 
and how this related to the expression profiles of the miRNAs examined. TNF and 
RANTES were both induced by M. tuberculosis (Figure 3.11 and 3.12). Conversely, 
M. tuberculosis did not stimulate the production of MIP-1α and MIP-β. AMJ2.C11 
and IC-21 cells constitutively expressed MIP-1α and MIP-β (Figure 3.13) regardless 
of infection, indeed in both cell lines M. tuberculosis infection actually resulted in a 
decline in MIP-1α and MIP-1β levels in the supernatant. This may have been due to 
inhibition of the expression of these chemokines by the infection, or alternatively 
other cells in the well themselves took up the MIPs. Little is known regarding the 
production of chemokines by AMJ2.C11 and IC-21 cells. MIP-1α and MIP-β are 
produced by macrophages during the initial infection stage to recruit and activate 
circulating polymorphonuclear leukocytes (Driscoll et al., 1993, Driscoll, 1994). 
However, even without infection, these two macrophage cell lines already produced 
these chemokines. As for MCP-1, another chemokine known to attract monocytes, 
levels were significantly upregulated by M. tuberculosis infection (Figure 3.13).  
 
This study showed that all the chemokines and cytokines parameters measured here, 
except MIP-1α and MIP-β, were induced by M. tuberculosis. This might help explain 
how the AMJ2.C11 cells are able to reduce intracellular bacteria growth by 48 hours. 
However, IC-21 cells showed similar patterns of cytokine and chemokine expression 
but did not show the same ability to contain M. tuberculosis growth. Interestingly, all 
6 miRNAs examined in this study were upregulated by 6 hours and returned or were 
returning to baseline by 24 hours. We also observed in one experiment that some 
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miRNAs started decreasing by 10 hours (data not shown). In contrast, in the 
AMJ2.C11 cells upregulation of these same miRNAs were slower and peaked at 24-
48 hours post infection in the AMJ2.C11. From these data it cannot be concluded that 
the early expression of miRNAs in IC-21 was responsible for the inability of this 
peritoneal macrophage cell line to contain M. tuberculosis. As discussed above (Ma et 
al., 2011a), the upregulation of miR-29, 99, 125 and 146a, have all been associated 
with inhibiting the production of TNF and other proinflammatory cytokines (Singh et 
al., 2013, Rajaram et al., 2011, Li et al., 2013). AMJ2.C11 cells showed slower but 
prolonged upregulation of these miRNAs, while miRNAs level return to baseline by 
24 hours in IC-21 cells. This finding might indicate that IC-21 cells would mount a 
swifter inflammatory response leading to increased intracellular bacteria killing. 
However, the result was the opposite. This study indicates that IC-21 cells cannot 
contain mycobacterial infection as efficiently as AMJ2.C11 cells. The differences in 
the expression patterns between the alveolar macrophage cell line compared to the 
peritoneal cell line may reflect the situation in vivo where the alveolar macrophages 
provide protection against the respiratory infection M. tuberculosis. Indeed the slower, 
longer expression of these, and most likely other, miRNAs may help the macrophages 
mount a sustained protective response against M. tuberculosis. Our data do indicate 
also that this increased protection was not directly due to changes in the expression of 
any of the cytokines or chemokines measured in this study. 
 
M. tuberculosis also induced miR-146a in human monocyte-derived macrophages 
(Barry S. et al., personnel communication unpublished data), however, miR-146a was 
downregulated in the serum and sputum from patients with tuberculosis (Liu et al., 
2014b, Barry et al., 2015). miR-146a was markedly upregulated even until 48 hours in 
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AMJ2.C11 cells, and upregulated within 2 hours after M. tuberculosis infection in IC-
21 cells. As miR-146a was differently expressed in human macrophages, patient’s 
sample and murine cell lines, this study was interested to further examine the 
functional effects of miR-146a in AMJ2.C11 and IC-21 cells, whether modulation of 
miR-146a by silencing or overexpressing would affect the proinflammatory cytokine 
profile and control of M. tuberculosis growth. This will be examined in Chapter 4. 
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4.1 Introduction 
Alveolar macrophages are among the first cells to encounter M. tuberculosis and the 
predominant cell type where the bacilli reside and replicates. The activation of 
macrophages following M. tuberculosis infection is primarily initiated by stimulation 
of specific Toll-like receptors (TLRs) which activate a cascade of MyD88-dependent 
signal transduction to induce proinflammatory cytokines release (Flynn and Chan, 
2001) TNF is one of the most important proinflammatory cytokines produced by 
macrophage, and is essential for controlling M. tuberculosis. TNF is crucial in the 
formation of the granuloma which confines and restricts the growth of the bacteria. 
When TNF is depleted, such as in individuals receiving anti TNF therapy to treat 
autoimmune diseases, increased reactivation of latent tuberculosis was observed in the 
patients (Gardam et al., 2003, Miller and Ernst, 2009). While a sufficient 
inflammatory response is required to clear the pathogen, unrestrained inflammation 
has deleterious effects to the host. 
 
It is well documented that miRNAs are also important in the regulation of the immune 
system. miRNA regulate the production of multiple proinflammatory molecules, such 
as cytokines at the post-transcriptional level (Fairfax et al., 2015, Quinn and O'Neill, 
2014, Hou et al., 2009). miRNAs act to fine-tune the immune system so that the 
inflammatory response is tightly controlled. Taganov and colleagues (Taganov et al., 
2006) reported the first evidence that miR-146a was acting as a negative feedback 
regulator of the proinflammatory response  of the human monocytic THP-1 cell line 
following LPS stimulation. miR-146a was shown to negatively regulate proteins in 
the TLR-dependent signalling pathway, leading to the repression of NF-κB activation. 
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As a result, the production of proinflammatory cytokines including IL-6, TNF-α and 
IL-8 was inhibited. Conversely, in miR-146a knock out mice, hyper-responsiveness to 
LPS and an exaggerated proinflammatory response following endotoxin challenge 
were observed (Boldin et al., 2011).  
 
In this study, miR-146a was significantly upregulated in macrophages following 
infection with either M. tuberculosis or the less virulent vaccine strain M. bovis BCG. 
The upregulated miR-146a observed by 6 hours (Figure 4.5) aligned with the findings 
demonstrated by Taganov with THP-1 cells after LPS stimulation (Taganov et al., 
2006). Our group also observed that peripheral-monocyte derived human 
macrophages showed upregulated miR-146a following M. tuberculosis infection by 6 
hours (S Barry et al unpublished observations). Therefore, the effect of modulating 
miR-146a expression in murine alveolar and peritoneal macrophages during M. 
tuberculosis infection was examined. 
 
This study used miRCURY LNA™ miRNA Power Inhibitor and mimic for studying 
the effect of gain or loss-of-function of miR146a on the macrophage response to M. 
tuberculosis infection. Locked Nucleic Acid (LNA™) nucleosides are a class of 
nucleic acid analogues that locks the ribose ring by a methylene bridge linking the 2’-
O atom and the 4’-C atom (Figure 4.1). LNA™ nucleosides are able to form base 
pairs according to standard Watson-Crick pairing rules and pair with a complimentary 
nucleotide strand when LNA is incorporated into a DNA or RNA oligonucleotide. 
The resultant complex is stable and has high melting temperature (Tm). LNA™-based 
oligonucleotides, as used in this study, are the complexes with DNA or RNA 
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nucleotides locked with one or more LNA™ nucleosides, providing a sensitive and 
specific analysis of short RNA and DNA targets. 
 
LNA™ Power Inhibitor has the antisense oliglonucleotides bound to LNA. Power 
Inhibitor is the third generation of inhibitor product as it comes with a fully 
phosphorothioate (PS) modified backbone. This modification improves the stability of 
miRNA inhibitors against enzymatic degradation. The mechanism of antisense 
oligonucleotides targeting mature miRNAs is shown in Figure 4.2. 
miRCURY LNA™ microRNA Mimics contain a microRNA (guide) strand with a 
sequence precise to the annotation in miRBase which binds the passenger strands (two 
LNA™-enhanced RNA strands). When the LNA™ microRNA Mimic is transfected 
into the cells, the segmented nature of the complementary passenger strands ensures 
that only the microRNA (guide) strand is incorporated into the RNA induced 
silencing complex (RISC). As a result, the complementary strands do not induce any 
miRNA activity (Figure 4.3). 
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4.2 Result 
4.2.1 miR-146 inhibitor or mimic transfection  
Evidence regarding the role of miR-146a in regulating immunity has been growing in 
recent years (Taganov et al., 2006, Perry et al., 2009, Liu et al., 2014a). Alveolar 
macrophages are the main target cells infected by M.tuberculosis; however, the 
biological effect of miR-146a on the function of alveolar macrophages remains 
unknown. Therefore, in this study the effects of inhibition or overexpression of miR-
146a on the response to M.tuberculosis infection was examined in both alveolar and 
peritoneal macrophage cell lines. This comparison allows the response of 
macrophages in the lung to be compared with what would be an extrapulmonary site 
on the response to M.tuberculosis infection. 
 
This miRNA transfection study is a pioneer study in our Tuberculosis Research Group. 
Little is known from the published articles regarding miRNA transfection efficacy in 
alveolar and peritoneal macrophage cell lines and on the response to M. tuberculosis 
infection. Before the effect of inhibition or overexpression of miR-146a on the control 
of M. tuberculosis infection could be determined, a series of experiments were 
undertaken to determine which transfection reagents can deliver a succesful 
transfection on the type of cells to be used in this study, and to determine the optimal 
dose of inhibitor and mimic required. Fortunately, the Centenary Insitute Vascular 
Biology Research Group kindly provided HiPerFect transfection solution (QIAGEN, 
Victoria, Australia) and LNA human hsa-miR-155 inhibitor (Exiqon, Vedbaek, 
Denmark) for the preliminary transfection experiment. According to the manufacturer, 
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LNA human hsa-miR-155 inhibitor is compatible for in vitro murine models as 
human miR-155 and murine miR-155 have the same mature miRNA sequence (5’-
UUAAUGCUAAUCGUGAUAGGGGU-3’) found on miRNA datase 
www.miRBase.org. In order to determine which transfection reagent delivered a 
better miRNA transfection on the type of cells used in this study, a few different 
commercial transfection reagents were tested for transfecting LNA hsa-miR-155 
inhibitor (10nM) on murine alveolar cells. 
Table  4.1: List of 3 different commerical transfection reagents used in the prelimary 
experiment for hsa-miR-155 inhibitor transfection of alveolar cells 
Transfection reagents   Company 
TransIT-X2 Dynamic Delivery System Mirus Bio, Madison, WI, USA 
Lipofectamine 2000 Life Techonologies, Victoria, 
Australia 
HiPerFect Solution QIAGEN, Victoria, Australia 
 
Cells were plated on 24-well plates at a density according to each manufacturer’s 
protocol, and hsa-miR-155 inhibitor transfection was performed. After overnight 
incubation, RNA was extracted using Trizol as previously described (Chapter 2. 
Material and Methods) and concentration was determined by Fragment Analyzer 
(Advanced Analytical Technologies, Ames, USA). All samples had a RNA intensity 
number (RIN) of ≥ 8. The cDNA was synthesized as previously described and the 
effects of transfection with miR-inhibitor were assessed by RT-qPCR. 
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Table 4.2: Threshold cycle (Ct) value of miR-155 in AMJ2.C11 cells treated with 3 
different types of transfection reagents and LNA hsa-miR-155 inhibitor or scrambled 
control (10nM) measured by RT-qPCR 
Transfection 
reagents 
miR-155 
inhibitor 
miR-155 
scramble 
Negative 
control 
Mirus Bio undetermined* 34.13 35.39 
Lipofectamine 2000 39.73 34.64 34.97 
HiPerFect solution undetermined* 33.97 34.19 
*undetermined: Ct value greater than 40 cycles 
 
Table 4.2 showed that 3 different transfection reagents successfully transfected 
alveolar cells with LNA hsa-miR-155 inhibitor (10 nM), resulting in a suppressed 
miR-155 expression level compared to either miR-155 scramble or negative control. 
To determine the optimal dose of miR-155 inhibitor required for the inhibition of 
miR-155 on alveolar and peritoneal macrophage cell lines, HiPerFect transfection 
reagent was selected for this study. HiPerFect solution was chosen because the 
preparation step was simple and fast and compar80able in efficiency to the other 
transfection reagents tested. A suitable concentration for miR-inhibitor transfection 
was determined. According to a miR-155 study on the production of reactive oxygen 
species (ROS) by murine macrophage (RAW267.4) after M. bovis BCG challenge, the 
concentration of LNA miR-155 inhibitor (Exiqon) at 30 nM successfully repressed the 
expression level of miR-155 measured by RT-qPCR (Wang et al., 2014). LNA hsa-
miR-155 used in this study is the third generation of LNA miRNA inhibitors, called 
Power Inhibitors™ (Exiqon), which comes with a fully PS modified backbone. This 
modification improves the stability of miRNA inhibitors against enzymatic 
degradation. As the efficacy of the third generation of miR-inhibitor is reportedly 
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better than the second-generation products 10 nM, 15 nM and 25 nM of the miR-155 
inhibitor were tested to determine the optimal inhibition with the lowest dose of miR-
inhibitor. 
 
Following the manufacturer’s protocol, cells were plated on 24-well plates at a density 
of 2x105 cells/100 µl and transfected with 10 nM, 15 nM and 25 nM of the miR-155 
inhibitor. The transfected cells were stimulated with lipopolysaccharide (LPS) 500ng 
and IFNɣ 100 U overnight. After overnight incubation, under the light microscope the 
confluency of the transfected AMJ2.C11 was lower regardless the concentration of 
miR-155 inhibitor used when compared to the confluency of the cells in the negative 
control wells. The decreased confluency in the miR-155 inhibitor transfected-cells 
might be caused by cell death induced by the transfection treatment or the inhibition 
of normal cell proliferation. RNA was extracted by using Trizol. The quantification 
and qualification of RNA, cDNA synthesis and the amplification of miRNA by RT-
qPCR were all performed as previously described (Chapter 2. Material and Methods). 
The threshold cycle of miR-155 expression alveolar and peritoneal cells treated with 
the different concentrations of miR-155 inhibitor is listed on Table 4.3 and 4.4. 
Table 4.3: Threshold cycle (Ct) value of miR-155 in AMJ2.C11 cells measured by RT-
qPCR after the transfection with different concentrations of  hsa-miR-155 inhibitor  
Sample 10 nM 15 nM 25 nM 
miR-155 inhibitor undetermined* 
 
37.57 34.01 
miR-155 inhibitor+LPS+ IFNɣ 33.15 33.92 34.68 
miR-155 scramble  30.57 30.06 31.31 
LPS+IFNɣ only 26.61 
Negative control 32.81 
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*undetermined: Ct value greater than 40 cycles 
Table 4.4: Threshold cycle (Ct) value of miR-155 in IC-21 cells measured by RT-
qPCR after the transfection with different concentrations of hsa-miR-155 inhibitor 
Sample 10 nM 15 nM 25 nM 
miR-155 inhibitor undetermined* 
 
undetermined* 37.562893 
miR-155 inhibitor+LPS+IFNɣ 34.95 33.55 36.79 
miR-155 scramble  28.73 28.87 28.81 
LPS+IFNɣ only 24.06294 
Negative control 29.40705 
*undetermined: Ct value greater than 40 cycles 
 
The resultant RT-qPCR amplification showed that even the lowest concentration of 
miR-155 inhibitor, 10 nM, suppressed the expresion level of miR-155 on both cell 
types compared to negative control (Table 4.3 and 4.4). However, only miR-155 
inhibitor at a concentration of 25 nM showed a consistent suppression of miR-155 on 
alveolar and peritoneal macrophage despite the stimulation of LPS and IFNɣ. In 
contrast, the transfection with any concentration of miRNA scramble control showed 
a similar miR-155 expression on both cell types compared to the negative control. 
Therefore, it was decided to use the higher 25 nM concentration of miR-inhibitor in 
this study.  
 
In order to determine the optimal concentration of miR-mimic, a few different 
concentrations were tested on both alveolar and peritoneal macrophages. Similar to 
LNA miRNA Power Inhibitor™, the third generation of LNA miRNA mimic used in 
this study is a more potent product than the second generation miRNA mimic. In 
addition, published studies have shown that in general the mimics are used at a much 
lower concentration than the inhibitors. The optimization study tested 2 nM, 5 nM and 
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10 nM of miR-146a mimic compared against the mimic control. The transfection was 
performed using HiPerfect transfection reagent according the the manufacturer’s 
protocol. Again transfected cells were stimulated with LPS and IFNɣ 100U overnight. 
Table 4.5 showed the threshold cycle (Ct) value of the miR-146a mimic-transfected 
cells as measured by RT-qPCR. 
 
Table 4.5: Threshold cycle (Ct) value of miR-146a AMJ2.C11 and IC-21 cells 
measured by RT-qPCR after the transfection with different concentrations of hsa-miR-
146a mimic 
Samples AMJ2.C11 IC-21 
2 nM 5 nM 10 nM 2 nM 5 nM 10 nM 
miR-146a mimic 18.84 16.07 16.22 16.78 16.23 15.83 
miR-146a mimic + LPS ɣ  34.25 17.85 15.16 18.09 15.53 15.69 
miR-146a control 22.07 21.79 21.64 24.34 24.54 23.05 
LPS 500ng + IFNɣ 100 U 20.36 19.95 
Negative control 21.99 20.34 
 
The resultant RT-qPCR amplification showed that the miR-146a mimic at the 
concentration of 10 nM provided a more efficient upregulation miR-146a on both cell 
types with or without LPS and IFNɣ stimulation compared to 2 nM or 5 nM of miR-
146a mimic. Although both 2 nM and 5 nM of miR-146a mimic increased miR-146a 
levels, miR-146a levels slighlty decreased in the cells stimulated LPS and IFNɣ. 
Therefore, miR-146a mimic at the concentration of 10 nM was chosen for this study. 
With the optimal concentrations of the mimic and inhibitor determined, AMJ2.C11 
and IC-21 cells were plated on 24-well plates at a density of 2x105 cells/100 µl and 
transfected with 25 nM of LNA miR-146a inhibitor or scramble control (Exiqon), 10 
nM of LNA-miR-146a mimic or mimic control (Exiqon) with the HiPerfect 
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transfection reagent (QIAGEN). 500 µl DMEM or RPMI with 10% FCS and IFNɣ 
100U, without antibiotics was added 6 hours post transfection. The cells were 
incubated overnight before infection with M.tuberculosis H37Rv at a 1:1 ratio. Prior 
to infection, the morphological appearance of AMJ2.C11 and IC-21 cells was 
observed under the light microscope. It was noted that the confluency of both types of 
cells did not change after overnight incubation, whereas the confluency of non-
transfected cells increased. The confluency of post-transfected AMJ2.C11 or IC-21 
was estimated ~30% less than non-transfected cells, indicating that the transfection 
treatment inhibited normal cell proliferation. Post transfection however, both 
AMJ2.C11 or IC-21 cells appeared viable, cells had a uniform size and showed  
similar morphological characteristics compared to non transfected cells.    
 
Four hours after M. tuberculosis infection, unincorporated extracellular bacteria were 
washed away, excluding the supernatants of 6 hours sample group which were 
harvested for cytometric bead assay without washing. Under the light microscopy, the 
morphological appearance of the post transfected AMJ2.C11 cells following M. 
tuberculosis infection, visually did not look any different to the infection only group 
or the negative control group. In contrast, post transfection IC-21 cells infected with 
M. tuberculosis infection did show visually apparent differences, with non-uniform 
sizes of cells with both swollen and shrunken cells observed. In addition, more cell 
death was evident with cells debris apparent. The confluency of post-transfected IC-
21 cells was slightly less, estimated ~30%, than the confluency of the cells prior to M. 
tuberculosis infection.  This same pattern of cell death was seen regardless of what the 
cells were transfected with whether it was the mimic or inhibitor or the scrambled 
control. Similar findings were also noted in both AMJ2.C11 and IC-21 cells after M. 
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tuberculosis infection at a 5:1 ratio at 6 hours. This suggest that while a lower dose of 
M. tuberculosis infection (a 1:1 ratio) did not induce any apparent morphological 
changes in post transfection alveolar AMJ2.C11 macrophages, the peritoneal 
macrophage IC-21 cell line, was more sensitive to the dual insult of transfection and 
mycobacterial infection. 
 
Nevertheless, transfected infected cells and all the control wells were harvested at 6, 
24, and 48 hours post M. tuberculosis infection in Trizol. Prior to harvesting the cells 
at pre-determined time points, the cells were observed under the light microscopy. 
AMJ2.C11 and IC-21 cells in negative control groups showed a significant cell 
growth with the confluency up to 100% by 24 hours. The morphological features of 
post-transfected cells did not show any difference compared to the infection groups or 
negative control groups. However, as the inhibition of cell growth induced by 
transfection, the confluency of post-transfected cells was half that of the cells in 
negative control group.  
 
miR-146a expression was measured by RT-qPCR using Let-7a as a reference gene. 
The resultant RT-qPCR amplification showed that miR-146a was upregulated in M. 
tuberculosis H37Rv-infected AMJ2.C11 and IC-21 cells during the course of 
infection (Figure 4.4A and 4.4B). The expression of miR-146a on AMJ2.C11 cells 
displayed a different pattern compared to IC-21 cells. miR-146a was upregulated in 
AMJ2.C11 cells by 6 hours post infection and further increased by 24 hours. Although 
miR-146a level decreased slightly by 48 hours (Figure 4.4A), 3 repeated experiments 
demonstrated that miR-146a level remained elevated at 48 hours post infection.  
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In contrast, H37Rv-infected IC-21 cells showed upregulated miR-146a expression by 
6 hours, with the expression levels returning to the levels seen in uninfected 
macrophages by 24 hours (Figure 4.4B). 3 repeated experiments demonstrated that 
miR-146a level increased by 6 hours in IC-21 cells following M. tuberculosis 
infection with the expression levels returning to the baseline seen in uninfected 
macrophages by 48 hours. As shown in Figure 4.4 this different pattern of miRNA 
expression between AMJ2.C11 and IC21 was not only seen with miR-146a, but with 
other miRNAs including miR-155, miR-29a, miR-99b and miR-125 as demonstrated 
in Chapter 3 (Figure 3.8). Interestingly, this unique expression pattern was only seen 
following virulent M. tuberculosis infection and not following M. bovis BCG 
infection. 
 
There was a significant change in miR-146a levels in both AMJ2.C11 and IC-21 cells 
transfected with miR-146a inhibitor and infected with M. tuberculosis H37Rv 
infection. The miR-146a inhibitor significantly suppressed miR-146a expression in 
both AMJ2.C11 and IC-21 cells at all time points measured (Figure 4.4A and 4.4B). 
This inhibition was long lasting as even by 48 hours post infection the miR-146a level 
was reduced by more than 7 fold in AMJ2.C11 and 10 fold in IC-21 compared to the 
H37Rv infection group. Interestingly, it was noted that transfection with the 
scrambled vector lead to a sustained increase in miR-146a expression at all time 
points in the AMJ2.C11 cells compared to the infection group; a similar increase in 
miR-146a expression in IC-21 cells was noted at 6 and 24 hours. 
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The transfection of the miR-146a mimic on AMJ2.C11 and IC-21 cells following M. 
tuberculosis infection also showed a significant upregulation of miR-146a (Figure 
4.4.A and 4.4.B). The miR-146a mimic led to increased miR-146a levels in both 
AMJ2.C11 and IC-21 cells at all indicated time points. The overexpression induced 
by the miR-146a mimic was highest at 6 hours post infection in both cell types. Cells 
treated with the miR-146a mimic control showed equivalent levels of miR-146a as 
seen in H37Rv-infected macrophages alone. 
 
To determine whether the overexpression or inhibition of miRNA levels induced by 
miR-146a inhibitor or mimic was targeted specifically to miR-146a and did not 
interfere with the expression levels of other miRNAs, expression of the most 
upregulated miRNA noted in Chapter 3, miR-155, was examined. Transfection with 
miR-146a inhibitor following M. tuberculosis infection did not suppress the 
expression levels of miR-155 in both cell types compared to the no transfection group 
(Figure 4.5.A and 4.5.B). Interestingly, miR-146a inhibitor and scrambled control 
wells showed upregulation of miR-155 levels in IC-21 cells compared to the no 
transfection group at 6 and 24 hour with the expression levels returning to the levels 
seen in infection group by 48 hours.  
 
miR-146a mimic upregulated miR-155 as much as the infection in AMJ2.C11 cells. 
But, mir-146a mimic significantly induced a higher miR-155 than M. tb infection in 
IC-21 cells. Whether the upregulation of miR-155 by miR-146a would affect the 
peritoneal macrophages response is not known. 
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4.2.2 Does inhibition or overexpression of miR-146a in AMJ2.C11 
and IC-21 cells affect the release of proinflammatory cytokines or 
chemokines? 
Transfection of both AMJ2.C11 and IC-21 cells with the miR-146a inhibitor or mimic 
successfully induced the inhibition or overexpression of miR-146a at all time points 
measured during the course of M. tuberculosis infection. To assess whether the 
modulation of miR-146a expression influenced the production of cytokines or 
chemokines at the protein level, the concentration of several known proinflammatory 
cytokines and chemokines in the supernatants collected at 6, 24 and 48 hours post 
infection was measured. 
 
M. tuberculosis H37Rv infection induced a significant increase in TNF levels in all 
infected AMJ2.C11 cells at 6 hours (Figure 4.6B), with levels remaining significantly 
elevated up to 48 hours. These data mirror the data seen in Figure 3.11A and 3.11B, 
showing that M. tuberculosis induced a considerable amount of TNF. Increased TNF 
was driven by the M. tuberculosis infection and was not significantly modified by 
transfection with either the miR-146a mimic or inhibitor.  
 
A study of the production of RANTES in human alveolar epithelial cells (A549 cells) 
found inhibition of miR-146a expression increased the production of RANTES and 
inhibition of RANTES increased the production of miR-146a (Perry et al., 2008). In 
this study, uninfected macrophages did not produce any RANTES (Figure 4.7A). 
Infection with M. tuberculosis induced a significant increase in RANTES during the 
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course of infection. Transfection with either the miR-146a inhibitor or the scrambled 
control further increased the release of RANTES by the M. tuberculosis infected cells 
at 6 hours. Interestingly, regardless miR-146 mimic or inhibitor, the post transfected 
alveolar macrophages produced more RANTES than the M. tuberculosis infected cells 
alone, indicating that the process of transfection was increasing chemokine expression 
(Figure 4.7B). The only specific increase in RANTES was seen in the miR-146a-
mimic transfected cells at 6 hours only. 
 
Even without M. tuberculosis infection, the alveolar macrophage cell line 
constitutively releases a large amount of MIP-1α (Figure 4.8A). M. tuberculosis 
infection actually reduced the level of MIP-1α detected in the supernatant, with levels 
remaining below that of the uninfected cells. The reduction of MIP-1α in M. 
tuberculosis-infected cells was observed up to 48 hours. It might suggest that 
Mycobacterium infection inhibits the production of MIP-1α by alveolar macrophage, 
or possibly other cells in the well are using the released MIP-1α while controlling the 
intracellular pathogen. Figure 4.8A shows that transfection of the AMJ cells with the 
miR-146a mimic or inhibitor even further reduced MIP-1α levels, but this was again 
due to transfection and not the specific miR-146a mimic or inhibitor. 
 
MIP-1β was also constitutively produced (<1000 pg/ml) by uninfected alveolar 
macrophages (Figure 4.8B). However, M. tuberculosis infection led to a significant 
increase in MIP-1β in the supernatant of the AMJ2.C11 cells by 6 hours (Figure 4.8B), 
with levels rapidly declining to those levels seen in uninfected cells by 48 hours. 
Interestingly, AMJ2.C11 cells transfected with either the miR-146a inhibitor or the 
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scrambled control produced more MIP-1β at 48 hours, indicating again that this was 
due to the effect of transduction and not a specific effect of the miR-146a inhibitor. 
Interestingly, by 48 hours the miR-146a mimic treated cells did show significantly 
more MIP-1β compared to M. tuberculosis-infected cells and the mimic control at 48 
hours. 
 
The cytokines or chemokines produced by the peritoneal macrophage cell line IC-21, 
were also examined. The pattern of MIP-α production was similar to that seen in the 
alveolar macrophage cell line AMJ2.C11. Uninfected peritoneal macrophages 
constitutively expressed MIP-1α with lower levels detected at 24 and 48 hours (Figure 
4.9A). M. tuberculosis infection alone had no significant effect on MIP-1α released 
into the supernatant. IC-21 cells transfected with either the miR-146a inhibitor or the 
scrambled control produced a relatively similar amount of  MIP-1α compared to the 
infection only group. Transfection with either miR-146a mimic or the mimic control 
also did not induce a significant release of MIP-1α.   
 
MIP-1β was also constitutively produced by uninfected peritoneal macrophages 
(Figure 4.9.B). M. tuberculosis infection did not induce MIP-1β release. By 24 hours, 
transfection with either miR-146a inhibitor or the scrambled control induced a 
significant increase in MIP-1β, suggesting it was the effect of transduction. 
Transfection with miR-146a mimic induced a significant increase in MIP-1β by 24 
and 48 hours. In summary, miR-146a mimic, miR-146a inhibitor and the scrambled 
control all increased the level of MIP-1β.  
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Figure 4.10B and 4.10C showed that M. tuberculosis infection induced the production 
of TNF by IC-21 cells with levels significantly elevated by 24 hours and even more 
increased by 48 hours. In previous repeated experiments (Figure 3.10C and 3.10D) M. 
tuberculosis also started to induce TNF by 6 hours and the level became significant by 
24 hours. Neither the inhibition nor overexpression of miR-146a had a significant 
effect upon TNF levels over that induced by M. tuberculosis infection. 
 
As for RANTES, M. tuberculosis infection induced significant RANTES release by 
the IC-21 cells. Transfection with the miR-146 inhibitor or the scrambled control both 
induced a similar increase in RANTES level, indicating an effect of the transduction 
itself, though there was a trend towards more RANTES expression by the inhibitor 
group, which did reach significance at 24 hours (Figure 4.11B). However, cells 
treated with the miR-146a mimic did show significantly more RANTES in the 
supernatant at all three time points compared to both the mimic control and the M. 
tuberculosis alone infected groups. These data suggest that the increase in RANTES 
seen in the mimic group may be due to an effect of transduction as both the miR-146a 
mimic and miR-146 inhibitor groups showed a similar effect on RANTES expression. 
 
4.2.3 Intracellular M. tuberculosis H37Rv growth  
Despite not having major effects on the proinflammatory cytokines and chemokines 
measured the effect of the miR-146a inhibitor and mimic on controlling the growth of 
M. tuberculosis was examined. In spite of some apparent cell death due to the 
transfection, AMJ2.C11 transfected and untransfected cells took up the same amount 
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of bacteria, as evidenced by their bacterial load at 6 hours post infection (Figure 
4.12A). 
 
By 24 hours cells treated with the miR-146a inhibitor showed a modest but significant 
reduction of intracellular M. tuberculosis growth with a trend of  remaining lower at 
48 hours compared to miR-146 scramble control or the infection group. Transfection 
with either miR-146a mimic or the mimic control did not significantly increase 
bacterial growth in AMJ2.C11 cells. 
 
Non-transfected IC-21 cells took up fewer bacteria compared to AMJ2.C11 cells and 
the bacterial load increased by 24 hours (**p<0.01, not listed on Figure 4.12B). There 
was no difference in the bacterial load in the cells transfected with either miR-146a 
inhibitor or the mimic compared to the control transfected cells. All the transfected 
had a lower bacteria burden at 24 and 48 hours compared to the untransfected cells. 
This was possibly caused by the cell death seen in the transfected, infected wells, with 
less viable cells to be infected with M. tuberculosis. Overall these results indicate that 
the inhibition or overexpression of miR-146a did not lead to any significant effect on 
the growth of M. tuberculosis in IC-21 cells. 
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4.3 Discussion 
Multiple studies have identified miR-146a as an important immune regulator, 
modulating the immune response following LPS stimulation, in cancer and infections 
including Mycobacterium (Boldin et al., 2011, Park et al., 2015, Perry et al., 2008, 
Saba et al., 2014, Li et al., 2013). miR-146a is thought to orchestrate this immune 
regulation by targeting key molecules, including IRAK1 and TRAF6 (Li et al., 2013, 
Liu et al., 2014b, Taganov et al., 2006). These molecules are important in the 
TLR/MyD88-dependent NF-κb proinflammatory signalling pathway. In 2003, Li and 
colleagues found that the inhibition of miR-146a increased the level of IRAK-1 and 
TRAF6 mRNA and protein (Li et al., 2013). They demonstrated that miR-146a 
directly targeted the 3’UTR of IRAK-1 and TRAF6 mRNA, resulting in the 
suppression of the NF-κb signalling pathway. The downstream result of this was the 
downregulation of NF-κb induced genes including IL-6, IL-1β, TNF and MCP-1. 
Another study documented that a high concentration of IL-1β induced increased 
expression of miR-146a, which in turn negatively regulated RANTES and IL-8 
expression (Perry et al., 2008). These data indicate that during acute or severe 
inflammation, the induction of miR-146a is necessary for a negative feedback 
mechanism to tightly control the inflammatory response.  
 
This study (Figure 4.4A and 4.4B) found that the expression of miR-146a was 
strongly induced by M. tuberculosis infection, and it was hypothesized that 
modulation of miR-146a would affect the production of proinflammatory cytokines 
and the growth of intracellular M. tuberculosis. This study also aimed to assess if the 
effect of miR-146 inhibition or overexpression was the same in macrophage cell lines 
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derived from alveolar and peritoneal macrophages. As miR-146a is thought to be a 
negative immune regulator, i.e. increased miR-146a leads to the suppression of TNF 
and RANTES, the inhibition of miR-1416a was expected to increase the production of 
proinflammatory cytokines and, as a downstream consequence of this, enhance 
macrophage activation leading to enhanced bacterial killing. While the overexpression 
of miR-146a would suppress NF-κB-induced proinflammatory cytokines, allowing 
more intracellular bacterial proliferation. 
 
At the molecular level, the inhibition or overexpression of miR-146a by a miR-146a 
antagomir or mimic respectively, showed effective miR-146a modulation. Treatment 
with the miR-146a antagomir reduced miR expression by more than a 10-cycle 
decrease in miR-146a expression while mimic treated cells showed a 30-cycle 
increase in miR-146a levels (Figure 4.4). However, the overexpression or inhibition 
of miR-146 did not significantly alter the proinflammatory cytokines and chemokines 
measured in the supernatants of the M. tuberculosis infected cells. Of the analytes 
examined in this study TNF, MIP-1β and RANTES were released by both alveolar 
and peritoneal macrophage cell lines following M. tuberculosis infection. In addition, 
post-transfected cells, transfected with the miR-146a inhibitor or mimic or the miR-
146a mimic control or the scrambled control all stimulated these cytokines and 
chemokines. For example, the inhibition of miR-146a on the AMJ2.C11 macrophages 
induced more TNF production compared to the infection alone group (Figure 4.6); 
however, the scrambled control induced similar TNF production, indicating that the 
increased release of chemokines or cytokines was not specific to the inhibition or 
overexpression of miR-146a, but that the transfection treatment itself induced both the 
AMJ2.C11 and IC-21 cells to release proinflammatory proteins.  
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In this study inhibition or overexpression of miR-146a did not modulate TNF or 
RANTES in either type of macrophages infected with M. tuberculosis. These data 
differ from results demonstrated by Liu Z. et al. and Perry M. et al in human-
monocytic (THP-1) cell line and murine macrophage tum (RAW264.7) cell line, 
respectively (Perry et al., 2008, Liu et al., 2014b, Li et al., 2013), where they found 
that the inhibition of miR-146a increased mRNA and protein levels of IRAK-1 and 
TRAF6, resulting in the increase of IL-8. RANTES and TNF. These apparent 
differences in results may be due to the type of macrophage cell line infected, 
AMJ2.C11 and IC-21 cells lines were derived from C57BL/6 mice whereas as RAW 
cells were derived from Balb/c mice and THP-1 cells are a human cell line. The THP-
1 cells were infected with BCG and in my studies I infected the cells with M. 
tuberculosis which is a stronger stimuli and may have overcome the effects of the 
miR-146 inhibition, or stimulated other pathways leading to increased TNF 
expression. TNF expression in the AMJ2.C11 and IC-21 cells was more than ten 
times that seen in the THP-1 cells. 
 
In order to determine whether the transfection treatment alone might induce the 
production of proinflammatory cytokines, future studies should measure the level of 
cytokines in the supernatants collected from the cells transfected with different 
concentrations of miR-mimic or inhibitor without M. tuberculosis challenge. 
 
Although the production of cytokines following the modulation of miR-146a with the 
mimic or inhibitor was different from the initial expectation; there was however a 
small reduction in intracellular M. tuberculosis growth in the AMJ2.C11 cells treated 
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with miR-146a inhibitor (Figure 4.12A). This reduction in bacterial load was 
significant at 24 hours with a trend of bacterial reduction that did not reach 
significance seen at 48 hours. 
In the IC-21 cells, there was a trend that the transfected cells, regardless of what they 
were transfected with took up less bacterial initially compared to the M. tuberculosis 
infection group. This may have been because there were a reduced number of IC-21 
cells available to take up the bacteria due to cell death caused by the transfection. It 
was also noted that the IC-21 transfected M. tuberculosis infected cells did not look as 
healthy as infected cells alone, nor as healthy as transfected but uninfected cells. This 
reduction in viability needs to be assessed in future studies, including testing 
alternative transfection reagents to find a transfection procedure that is not toxic to the 
cells. When compared with the inhibitor or mimic control, transfection with either 
miR-146a inhibitor or mimic did not significantly affect intracellular bacterial growth 
in IC-21 peritoneal macrophages cell line. If this is because expression of miR-146a 
does not regulate control of M. tuberculosis growth in these cells, or the effect was 
masked by the toxicity of the transfection on the IC-21 cells requires further 
investigation but the data does indicate that modulation of miR-146a did not have an 
impact on bacterial growth.  
 
My findings suggest that inhibition of miR-146a may enhance the capacity of 
AMJ2.C11 alveolar macrophages to control the growth of M. tuberculosis.  The 
mechanism leading to this enhanced control remains to be determined. The 
proinflammatory cytokines measured in this study were generally not significantly 
modulated by either overexpression or inhibition of miR-146a, suggesting that they 
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were not directly responsible for the increased control of M. tuberculosis growth seen 
following inhibition miR-146a. 
 
It is well documented that miR-146a directly targets two key adaptor proteins of the 
NF-κb signalling cascade, IRAK1 and TRAF6, resulting in the suppression of NF-κb 
associated genes. Therefore, in future experiments it would be interesting to measure 
mRNA levels of IRAK-1 and TRAF6 to see whether overexpression or inhibition of 
miR-146a has an impact on its target genes at the post-transcriptional level. It may be 
that infection with M. tuberculosis itself is such a strong stimulus that alternative 
pathways upregulated by infection are increasing NF-κb signalling. It should also be 
noted that even if the modulation of miRa-146a does interfere with NF-κb signalling 
pathway via IRAK-1 and TRAF-6, multiple miRNAs also have similar target mRNAs, 
therefore, other miRNAs might override the effects of miR-146a modulation such that 
the production of inflammatory proteins are not affected (Singh et al., 2013). In order 
to enhance the effects of either the overexpression or inhibition of miR-146a, 
increasing the concentration of the mimics or inhibitors remains a consideration, 
though these results do indicate the miR-146a was successfully inhibited or 
overexpressed for up to 48 hours post infection and inhibition of miR-146a has only a 
modest impact on M. tuberculosis growth in AMJ2.C11 cells.  
 
The benefit of using a cell line model is its rapid reproducibility and availability. 
However, it was observed that the overnight transfection treatment not only inhibited 
the proliferation of AMJ2.C11 and IC-21 macrophage, but also seemed to reduce the 
number of peritoneal IC-21 cells in the wells. In contrast, the non-transfected cells, 
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including the cells in negative control group and the infection only group, continued 
to proliferate while being incubated before the infection. This resulted in a different 
number of cells across the samples, and could have lead to inaccuracy in the 
calculation for multiplicity of infection. However, when the number of bacteria taken 
up by either transfected or non-transfected cells at 6 hours was assessed, very little 
difference was seen in any group despite this concern. However, to overcome this 
issue, primary murine alveolar or peritoneal macrophage could be used to examine the 
modulation of miR-146a because primary differentiated macrophages will not 
continue to proliferate ex vivo.  Using primary alveolar macrophages is challenging as 
a normal mouse lung contains only around half to one million macrophages (Zhang et 
al., 2008). In addition, the miRNAs expression profile of primary murine alveolar or 
peritoneal macrophage has not been documented yet but will be compared in future 
studies to the results obtained in these experiments. 
 
Our research group is also examining miRNA expression profile in plasma from 
patients with tuberculosis, miRNAs studies using the mouse model provide additional 
information regarding the expression profile and functional effects of miRNAs in 
response to mycobacterial infection. Examining miRNAs expression profiles of 
murine macrophage cell lines can help to determine the functional roles of miRNAs 
identified in these studies. It is also necessary to compare the expression of miRNAs 
in response to M. tuberculosis in human and murine macrophages. The same 
homologues of miRNA may be expressed differently in TB patients, human cells 
infected with M. tuberculosis or in vivo in infected mice or in murine cell lines. For 
instance, miR-146a is significantly downregulated in the plasma and sputum from 
patients with tuberculosis, while miR-146a is significantly upregulated in murine 
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macrophage and human peripheral blood-monocyte derived macrophages (S Barry et 
al. unpublished observations)(Liu et al., 2014a). As the course of tuberculosis is slow 
and considered as a chronic inflammatory state, the downregulation of miR-146a in 
patients’ serum might indicate that reduced miR-146a expression is important to aid 
control M. tuberculosis. M. tuberculosis is a chronic infection and we still have a great 
deal to learn about how it impacts on the expression of miRNAs. Further we are still 
evaluating how infection in macrophages affects the levels of miRNA observed in the 
plasma. 
 
Li S and colleagues reported that miR-146a facilitates the growth of M. bovis BCG in 
RAW264.7 cell line (Li et al., 2013). The upregulation of miR-146a induced by 
mycobacterial infection suppressed TNF, MCP-1, IL-6 and IL-1β, resulting in  
conditions that promoted the growth of the bacteria. The result of my study did show 
the inhibition of miR-146a in AMJ2.C11 alveolar macrophage significantly reduced 
intracellular M. tuberculosis load by 24 hours, but the overexpression of miR-146a 
did not lead to any significant increase in bacterial growth. The reasons for these 
differences are not clear but may be due to the different cell lines examined or the use 
of virulent M. tuberculosis versus the less virulent M. bovis BCG. 
 
Little is known regarding the response of miR-146a against M. tuberculosis infection 
because most of miR-146a studies including the studies done by Li S et al and Liu Z 
et al used M. bovis BCG (Li et al., 2013, Liu et al., 2014a). It would be interesting to 
compare the functional effects of inhibiting and overexpressing miR-146a in either 
AMJ2.C11 or IC-21 cells following both M. bovis BCG and M. tuberculosis infection, 
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so that the proinflammatory cytokines profile and bacterial growth can be compared 
with the published studies done in human monocytic (THP-1) cell and murine 
macrophage RAW264.7. This would provide a better understanding of miR-146a 
gain-or-loss-of function effects in different macrophage populations against 
Mycobacterium infections of different virulence. 
 
As previously mentioned cell death was observed after transfection of IC-21 cells. In 
future studies the choice of transfection reagent should be revisited and tests on 
different transfection reagents and their effects on the viability of the cells, especially 
after mycobacterial infection examined. If IC-21 macrophages are naturally more 
susceptible to cell death after transfection, it indicates that IC-21 cell line might not be 
a suitable model for studying the modulation of miRNAs.   
 
This study demonstrated that AMJ2.C11 cells showed enhanced intracellular M. 
tuberculosis killing compared to IC-21 cells. This might reflect that the actual 
response of these macrophages during in vivo infection, where alveolar macrophages 
are the predominant cell type that contain M. tuberculosis. To further examine 
alveolar macrophage, it would be worthwhile to compare the response of primary 
murine alveolar macrophage and AMJ2.C11 alveolar macrophage cell line following 
M. bovis BCG and M. tuberculosis infection. Future studies should also measure the 
production of chemokines in alveolar macrophages after infection. This response 
could also be compared with the miRNA expression profile in the whole lung or 
purified lung cells isolated from Mycobacterium infected mice. This would provide a 
complete and robust understanding of how murine alveolar macrophages, both 
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primary cells and cell line, respond to Mycobacterium infection and increase our 
understanding of how miRNAs function to aid control of M. tuberculosis infection. 
 
In summary, the modulation of miR-146a in this study effectively altered the 
expression of miR-146a in the two infection models. Although the changes seen in the 
proinflammatory cytokines were more likely due to the effects of the transfection 
treatment itself, the inhibition of miR-146a did reduce intracellular M. tuberculosis 
growth in AMJ2.C11 cells. The role of miR-146a in controlling mycobacterial 
infection by alveolar macrophages requires further examination.  
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5. General discussion  
Recent discoveries have identified the diverse involvement of miRNAs in cell 
functions, disease and inflammation. miRNAs regulate their target genes at the post-
transcriptional level by binding to the 3’UTR of their target mRNA. Interestingly, a 
single mRNA can be regulated by multiple miRNAs and each miRNA has multiple 
target genes. It is estimated that ~60% of human genes are regulated by miRNAs. 
Dysregulation of miRNAs have been associated with a wide spectrum of diseases, 
including cancer, autoimmune disease and infection. The fact that tumour-related 
miRNAs are called oncomiRs is just one example of the impact of miRNAs in human 
diseases. Since their discovery by Lee and Ambros et al, the number of miRNAs 
associated with infectious diseases, autoimmune conditions, cancers and normal 
cellular development has been rapidly expanding (Lee et al., 1993, Ambros, 2004). 
Our understanding of the expression and function of miRNAs is however still in its 
infancy. For instance we have limited knowledge about what miRNAs are important 
in the response to mycobacterial infection, how this changes as the infection 
progresses, which miRNAs contribute to pathology and which to protective immunity. 
A more complete understanding of how infection modulates miRNA expression and 
the function of these miRNA may identify new targets for future therapeutic studies, 
or miRNA expression profiles that may be used as biomarkers of disease. 
 
In H. pylori infection, aberrant expression of miRNAs in infected patients compared 
with healthy subjects has been reported (Matsushima et al., 2011). A panel of 470 
human miRNAs of which 55 miRNAs were differentially expressed between infected 
subjects and healthy subjects. They found 30 miRNAs were significantly 
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downregulated due to infection. After the eradication of H. pylori, 14 out of 30 
downregulated miRNAs were restored. Many of the dysregulated miRNAs found in H. 
pylori infection were associated with H. pylori-gastritis. The restoration of miRNA 
post H. pylori treatment suggests that miRNA expression has potential as a candidate 
marker for monitoring treatment efficacy. Another published study has shown that the 
oncomiRs related to H. pylori-induced gastric cancer tissue were not restored even 
after the eradication of infection (Shiotani et al., 2012). Again, this suggests that 
miRNAs might be a valuable candidate for screening gastric cancer in H. pylori-
positive patients. 
 
A growing number of studies have reported the alteration of miRNAs expression 
profiles in cell-based and serum-based studies in response to mycobacterial infection 
(Harapan et al., 2013, Qi et al., 2012). Based on the microarray results, Qi et al found 
that 97 miRNAs were differentially expressed in the plasma of patients with active TB 
compared with healthy control. RT-qPCR validation and receiver operational curve 
(ROC) analysis confirmed that three miRNAs (miR-361-5p, miR-889 and miR-576-
3p) distinguished TB-infected patients from healthy subjects. An ongoing study in our 
group (Barry et al personnel communication), has also found that the expression of 
circulating miRNAs in serum from patients with TB were modulated compared with 
healthy subjects. Taken together, these data suggest that levels of serum miRNA have 
potential as biomarkers for detection of TB infection.   
 
Being less susceptible to degradation when compared with mRNA is one of the 
characteristics of miRNAs that make it a good candidate for biomarker studies. 
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miRNAs are stably expressed, not only in cells, but also in the body fluids such as 
plasma, urine and sputum. The availability of miRNAs in different types of body 
fluids might provide an easy and non-invasive sampling method, thereby increasing 
the feasibility of using miRNA biomarker in resource-poor settings. 
 
There has been notable variation in the reports of which miRNA are modulated by 
mycobacterial infection. miRNAs are heterogeneous by nature, a single miRNA can 
bind a few to hundreds of targets and a single gene can have multiple miRNAs bind 
and modulate its function. Moreover, different workflow strategies might influence 
the profiling study. For example, in functional miRNA study, some studies design 
their own primers, while others use commercial primers. Other factors including the 
choice of a suitable reference miRNAs, types of cells studied and the method used for 
data analysis can influence the final miRNA data. Apparent differences reported 
between different studies demonstrate that additional studies, comparing miRNA 
profiles and miRNA functions in different conditions, are required to enhance our 
understanding of how miRNAs function in health and disease. 
 
As different types of cells may have variable miRNA expression profiles depending 
on the stimulus, it is challenging to compare or correlate the pattern of miRNAs 
expression between different types of cells. In mycobacterial research some of the 
published findings about miRNA expression and function have been quite variable. 
For example, Rajaram et al found M. tuberculosis induced the downregulation of 
miR-155 in human macrophages, while Kumar et al found the upregulation of miR-
155 in murine macrophages (Kumar et al., 2012, Rajaram et al., 2011). In this 
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investigation we found differences in the expression patterns of two types of 
macrophage cell lines both derived from the same host (C57BL/6 mice). These 
differences may be due to the tissue the macrophages were derived from alveolar 
versus peritoneal, the function of these macrophages in their original host, or other as 
yet undetermined factors. 
 
However, we need to acknowledge the potential limitations of miRNA studies, which 
make the studies challenging yet interesting. Firstly, the reference genes used are not 
universal to any kind of sample. Using an inappropriate reference gene for 
normalization can result in altered miRNA expression profiles. Unlike mRNA 
measurements that commonly use 18S or GAPDH as an endogenous control, 
choosing a suitable reference miRNA is influenced by the cell or tissue type under 
investigation.  
 
A recent study published by our group demonstrated that RNU6, widely used as 
reference gene for the miRNA study, was not stably expressed in the serum of TB 
patients (Barry et al., 2015). Twelve candidate reference miRNAs, all of which had 
been used as reference miRNA in published studies were examined for their 
suitability as reference miRNAs for plasma based TB studies. The study examined TB 
patients and healthy controls from both China and Australia and interestingly found 
considerable differences in the baseline expression of several of the miRNAs 
examined. Differences of up to 7-10 RT-qPCR cycles were seen between miRNA 
levels in Australian and Chinese cohorts. These differences were due ethnic or 
geographical differences in the subjects and not disease status. Only 2 out of 12 
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miRNAs tested, miR-93 and miR-22 were suitable stable reference miRNAs for 
analysis of the combined Australia and China cohort. Other studies have also 
supported the finding that RNU6 is unsuitable for normalizing miRNA data from 
serum or plasma (Song et al., 2012, Benz et al., 2013, Appaiah et al., 2011). In this 
study it was found that RNU6 was also not stably expressed in the cell lines examined. 
When equivalent RNA, as determined by the highly sensitive fragment analyser, was 
loaded into the assay the level of RNU6 varied markedly between samples and even 
between replicates. Other cell based studies have used RNU6 for normalizing miRNA 
levels but in this study, as has been reported in other studies (Wang et al., 2014, Wang 
et al., 2013) it was identified that Let-7a was more suitable for normalizing RNA 
levels in samples. 
 
It is also apparent that the same miRNAs can be both proinflammatory and inhibitory 
depending on factors that are often not well understood. Some studies have shown 
that the overexpression of miR-155 can stabilize TNF by increasing TNF mRNA half-
life (Bala et al., 2011, Rajaram et al., 2011).  However, other studies have reported 
that miR-155 attenuates SHIP-1, a negative regulator of serine/threonine AKT, 
resulting in an increase of serine/threonine AKT, which is required for the survival of 
Mycobacterium in macrophages (Kumar et al., 2012). 
 
In this investigation, M. tuberculosis infection upregulated miR-146 expression in two 
murine macrophage derived cell lines. Interestingly, studies by colleagues in our 
group have found that miR-146a expression is significantly downregulated in the 
plasma of TB infected patients compared with healthy controls (Barry et al personnel 
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communication, unpublished observations). It would be interesting to know if miR-
146 expression is up or down regulated in infected human lung macrophages and if 
the release of miR-146 into the blood is reduced by TB infection. Whether that is 
directed by the host response or by the bacteria directly is also not known. Our 
understanding of miRNA is still in its infancy; thus, it is important to explore what are 
the factors that regulate miRNA expression and function.  
 
Preliminary studies described in Chapter 4, found that silencing miR-146a led to a 
small but significant decrease in bacterial growth at 24 hours post infection, despite 
having no major impact on the expression of a range of proinflammatory cytokines 
and chemokines including TNF. miR-146a is reported to have capacity to bind to 180 
different mRNA, these targets have not yet all been verified and the functional effect 
of miR-146a binding to most of these targets is unknown. In order to further study the 
functional effects of miRNA, blocking a target gene in conjunction with silencing or 
overexpressing an individual miRNA is worth investigating. miRNAs have multiple 
target genes because the 5’-end of the miRNA, known as “seed sequence”, is a highly 
conserved sequence used in target binding (Bartel, 2009). Recent discoveries have 
shown that it is possible to block a single target of an miRNA using a novel 
technology called “Blockmirs” (Young et al., 2013). Endothelial-specific cadherin 
(VE-cadherin) is a cell junctional molecule that regulates capillary tube formation. 
Young et al demonstrated that the downregulation of miR-27a was important to 
increase the level of VE-Cadherin during the angiogenesis process. The 
overexpression of miR-27a reduced VE-cadherin protein, resulting in the disruption of 
angiogenesis and capillary tube formation. Young et al has designed a Blockmir with 
a sequence specifically against the miR-27 binding site in the 3’-UTR of VE-Cadherin. 
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The administration of a single bolus infection of this Blockmir in mice with hindlimb 
ischemia led to a reduction of vascular leak and an enhanced recovery from ischemia. 
Again, demonstrating the therapeutic potential of miRNA modulation.  
 
It would be interesting to use this technology to block some the NF-κB regulated 
genes such as TNF, IL-8, RANTES, MCP-1 and IL-1β, that are upregulated by 
mycobacterial infection, to determine how blocking the binding of miR-146 to a 
specific mRNA influences the growth of intracellular Mycobacterium and the 
inflammatory response generated by the host. 
 
Despite the challenges in miRNA studies, emerging evidence has shown that miRNA 
are an important component of how the host regulates cell function and the response 
to infection. Examining how miRNAs are modulated in human diseases is worth 
exploring extensively and may hopefully identify targets for future therapeutic 
interventions. Our investigation of miRNAs expression in AMJ2.C11 and IC-21 cells 
has established a baseline of macrophage miRNA expression to be further examined 
in primary murine cells and in vivo. miRNA knockout mice provide an excellent 
opportunity to examine in vivo the effect of gene deletion on miRNA expression and 
function and to compare the similarities and differences in the response to TB 
infection in human and murine macrophages and in in vivo mouse models. These 
studies will enable us to continue to unravel the expression of function of miRNAs in 
regulating immunity to M. tuberculosis infection.  
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Figure 1.1. The biogenesis and post-transcriptional suppression of microRNAs.  
microRNA genes are transcribed by RNA polymerase II into primary microRNAs 
(Pri-miRNA). Pri-miRNAs are processed into 70- nucleotides pre-miRNAs which are 
exported into the cytoplasm and further processed into miRNA:miRNA* duplexes by 
Dicer. Only one strand of miRNA from miRNA:miRNA duplex is incorporated into 
the RNA-induced silencing complex (RISC). Once in the RISC, the miRNA becomes 
a mature miRNA which is ready to target 3’UTR of its target mRNA, resulting in 
translational repression or mRNA cleavage. Figure adapted from (He and Hannon, 
2004). 
	  
	  
	  
	  
	  
 
 
Figure 3.1.  Nitric oxide, TNF and IL-12 production profile of AMJ2.C11 and 
IC-21 cells following M. bovis BCG infection. 1x106 cells were stimulated with 
IFNɣ overnight prior to M.bovis BCG infection at a 5:1 or 1:1 MOI. 4-6 hours post 
infection the unincorporated bacteria was washed off. Supernatants were collected at 
the indicated time points. Nitric oxide was measured by using Griess reagent. Limit of 
detection (LOD) of NaNO2 was 5 nmol/ml. IL-12 and TNF were measured by ELISA. 
LOD of IL-12 was 312 pg/ml. Data are the mean ± SEM of triplicate samples of one 
of three replicate experiments. Differences between groups were analysed by unpaired 
by one-way ANOVA. **p<0.01, ***p<0.001 , and ****p<0.0001. 
 
 
	  
	  
	  
	  
 
 
Figure 3.2. Formula for calculating the relative expression of miRNA (2(-△△Ct)). 
Threshold cycle value (Ct) of target gene was normalized to a reference gene to 
minimize any variations in samples, experiments and measurements. Figure courtesy 
of QIAGEN.  
 
 
 
Figure 3.3. The comparison of threshold cycle value (Ct) between RNU6 and Let-
7a on AMJ2.C11 cells following M. bovis BCG infection at a 1:1 and 5:1 ratio. 
1x106 cells were stimulated with IFNɣ overnight prior to M.bovis BCG infection at 
the stated MOI. At the indicated time points RNA was extracted. RNA levels were 
equalised by Fragment Analyser and the relative expression of miRNA measured by 
RT-qPCR . RNU6 is commonly used as a reference gene; however, the expression of 
RNU6 in this study was influenced by the conditions; whereas the expression of Let-
7a remained stable regardless of the dose of infection. Data are the mean of duplicate 
samples. UI, uninfected. 
 
	  
	  
	  
	  
 
 
 
 
 
 
 
 
Figure 3.4. miRNA expression in AMJ2.C11 cells in response to M. bovis BCG  
infection. 1x106 cells were stimulated with IFNɣ overnight prior to M. bovis BCG 
infection at a 1:1 MOI. At the indicated time points RNA was extracted. The relative 
expression of miRNA measured by RT-qPCR was normalized to Let-7a and 
determined using 2-△△Ct . Data are the mean ± SEM of triplicate samples of one of 
three replicate experiments. Differences between groups were analysed by unpaired 
Student’s t test. Black bars with # or ns: 6 hours versus 24 hours infected. * or ns on 
figure: infected versus uninfected at the same time point, * p<0.05 and ## or ** 
p<0.01. UI, uninfected; ns, not significant. 
	  
 
 
 
	  
	  
	  
	  
 
 
 
 
 
 
 
Figure 3.5. miRNA expression in IC-21 cells in response to M. bovis BCG  
infection. 1x106 cells were stimulated with IFNɣ overnight prior to M. bovis BCG 
infection at a 1:1 MOI. At the indicated time points RNA was extracted. The relative 
expression of miRNA measured by RT-qPCR was normalized to Let-7a and 
determined using 2-△△Ct . Data are the mean ± SEM of triplicate samples of one of 
three replicate experiments. Differences between groups were analysed by unpaired 
Student’s t test. Black bars with # or ns: 6 hours versus 24 hours infected. * or ns on 
figure: infected versus uninfected at the same time point, # or * p<0.05, ** p<0.01 
and *** p<0.001. UI; uninfected, ns; not significant.   
 
	  
	  
	  
	  
 
Figure 3.6. miRNA expression in AMJ2.C11 following M. tuberculosis infection 
at a (A) 1:1 and (B) 5:1 MOI. 1x106 cells were stimulated with IFNɣ for overnight 
prior to infection with M. tuberculosis at a (A) 1:1 and (B) 5:1 MOI. 4-6 hours post 
infection unincorporated bacteria were washed off. At the indicated time points RNA 
was extracted in Trizol. The relative expression of miRNA measured by RT-qPCR 
was normalized to Let-7a and determined using 2-△△Ct. Data are the mean ± SEM of 
quadruplicate samples of one of three replicate experiments. Differences between 
groups were analysed by unpaired Student’s t test. Black bars with # or ns: 6 hrs 
versus 24 hrs infected. * or ns on figure: infected versus uninfected at the same time 
point, # or * p<0.05, ** p<0.01 and *** p<0.001. UI; uninfected, ns; not significant.   
	  
	  
	  
	  
 
Figure 3.7. The comparison of differential miRNAs expression profile in 
AMJ2.C11 cells infected with (A) M. tuberculosis or (B) M. bovis BCG. 
Differences between groups were analysed by unpaired Student’s t test. Black bars 
with # or ns: 6 hrs versus 24 hrs infected. * or ns on figure: infected versus uninfected 
at the same time point, # or *p<0.05 and  ## or **p<0.01. UI; uninfected, ns; not 
significant.     
	  
	  
	  
	  
 
Figure 3.8. miRNA expression in IC-21 cells following M. tuberculosis infection at 
a (A) 1:1 and (B) 5:1 MOI. 1x106 cells stimulated o/n with IFNɣ then infected with 
M. tb. 4-6 hrs post infection unincorporated bacteria was washed off and RNA 
extracted in Trizol. Relative expression of miRNA measured by RT-qPCR was 
normalized to Let-7a and determined using 2-△△Ct. Data are the mean ± SEM of 
quadruplicate samples of one of three representative experiments. Differences 
between groups were analysed by unpaired Student’s t test. Black bars with # or ns: 6 
hrs versus 24 hrs infected. * or ns on figure: infected versus uninfected at the same 
time point, # or *p<0.05, ## or **p<0.01, ### or ***p<0.001, and ****p<0.0001. UI; 
uninfected, ns; not significant.     
	  
	  
	  
	  
 
Figure 3.9. The comparison of differential miRNAs expression profile in IC-21 
cells between (A) M. tuberculosis and (B) M. bovis BCG infection. Differences 
between groups were analysed by unpaired Student’s t test. Black bars with # or ns: 6 
hrs versus 24 hrs infected. * or ns on figure: infected versus uninfected at the same 
time point, # or *p<0.05, ## or **p<0.01 and  ### or ***p<0.001. 
	  
	  
	  
	  
 
Figure 3.10. Distinctive miRNA expression pattern in AMJ2.C11 and IC21 cells 
with following M. tuberculosis infection at a 5:1 MOI. (A) AMJ2.C11 show a 
delayed expression of miRNAs compared with the earlier expression in (B) IC-21 
cells. miRNA expression levels were measured at 6, 24 and 48 hours in AMJ2.C11, 
and at 2, 6 and 24 hours in IC-21 cells. The relative expression of miRNAs measured 
by RT-qPCR was normalized to Let-7a and determined using 2-△△Ct. Data are the mean 
± SEM of quadruplicate samples. 
 
	  
	  
	  
	  
 
 
 
Figure 3.11. TNF production by AMJ2.C11 and IC-21 cells following M. 
tuberculosis infection. TNF produced by AMJ2.C11 cells (A and B) and IC-21 cells 
(C and D) stimulated with IFNɣ overnight prior to M. tuberculosis at an MOI of 1:1 
(blue bars) or 5:1 (red bars). Data are the mean ± SEM of quadruplicate samples of 
one of three representative experiments. Differences between groups were analysed 
by one-way ANOVA. ns, not significant; *p<0.05, **p<0.01, ***p<0.001 and 
****p<0.0001. 
	  
	  
	  
	  
 
 
 
Figure 3.12. RANTES production by AMJ2.C11 and IC-21 cells following M. 
tuberculosis infection. RANTES production by AMJ2.C11 cells (A and B) and IC-21 
cells (C and D) stimulated with IFNɣ overnight prior to M. tuberculosis infection at an 
MOI of 1:1 (blue bars) or 5:1 (red bars). Data are the mean ± SEM of quadruplicate 
samples of one of two representative experiments. Differences between groups were 
analysed by one-way ANOVA. ns, not significant; *p<0.05, **p<0.01, ***p<0.001 
and ****p<0.0001. 
	  
	  
	  
	  
 
	  
	  
	  
	  
 
 
Figure 3.13. AMJ2.C11 and IC-21 cells constitutively express MIP-1α and MIP-
1β regardless of M. tuberculosis infection. Uninfected AMJ2.C11 (A, B) and IC-21 
(C, D) cells released MIP-1α within 6 hours and 2 hours, respectively. M. tuberculosis 
infection did not increase MIP-1α release. Similarly, MIP-1β was produced by 
uninfected AMJ2.C11 (E, F) and IC-21 (G, H) cells. M. tuberculosis- infected 
AMJ2.C11 and IC-21 cells did not release more MIP-1β than uninfected cells. Data 
are the mean ± SEM of quadruplicate samples of one of two representative 
experiments. Differences between groups were analysed by one-way ANOVA. ns, not 
significant; *p<0.05, **p<0.01, ***p<0.001 and ****p<0.0001. 
 
 
	  
	  
	  
	  
 
 
Figure 3.14. Increased MCP-1 production by AMJ2.C11 and IC-21 cells 
following M. tuberculosis infection. MCP-1 produced by AMJ2.C11 cells (A and B) 
and IC-21 cells (C and D) stimulated with IFNɣ overnight prior to M. tuberculosis 
infection at an MOI of 1:1 (blue bars) or 5:1 (red bars). Data are the mean ± SEM of 
quadruplicate samples of one of two representative experiments. Differences between 
groups were analysed by one-way ANOVA. ns, not significant; *p<0.05, **p<0.01, 
***p<0.001 and ****p<0.0001. 
 
 
 
 
 
 
	  
	  
	  
	  
 
 
 
 
Figure 3.15. Different pattern of M. tuberculosis growth in alveolar AMJ2.C11 
cells compared with peritoneal IC-21 cells. AMJ2.C11 cells showed a decrease in 
intracellular M. tuberculosis by 48 hours post infection, while peritoneal IC-21 cells 
showed increased bacterial growth by 24 hours regardless of the dose of infection. 
AMJ2.C11 (A, B) and IC-21 (C, D) cells were challenged with M. tuberculosis at an 
MOI of (A) 1:1 or (B) 5:1. 2-6 hours post infection unincorporated bacteria was 
washed off. Cells were treated with Triton X-100 and serial dilutions of the lysates 
were plated on 7H11 agar. Data are the mean ± SEM from quadruplicate samples. 
Differences between groups were analysed by one-way ANOVA. ns, not significant; 
***p<0.001 and ****p<0.0001.  
 
 
 
 
 
	  
	  
	  
	  
 
 
 
 
 
 
 
 
 
Figure 3.16. Intracellular growth of M. tuberculosis in alveolar (A) AMJ2.C11 
and (B) peritoneal IC-21 following M. tuberculosis infection at an MOI of 1. Data 
are the mean ± SEM of triplicate samples. Differences between groups were analysed 
by one-way ANOVA. ns, not significant. **p<0.01. 
 
 
 
 
 
 
 
	  
	  
	  
	  
 
	  
	  
Figure 4.1. The structure of LNA™. The ribose ring is connected by a methylene 
bridge (orange) between the 2’-O and 4’-C atoms thus “locking” the ribose ring in the 
ideal confirmation for Watson-Crick binding.  When incorporated into a DNA or 
RNA oligonucleotide LNA™ makes the pairing with a complimentary nucleotide 
strand more rapid and increases the stability of the resulting duplex. Figure and figure 
legend courtesy of Exiqon. Adapted from http://www.exiqon.com/lna-technology. 
 
 
 
Figure 4.2. The inhibition of miRNA function by antisense oligonucleotide. 
miRNA genes are transcribed through a series of RNA polymerases in nucleus and 
cytoplasm, resulting in short ~22 nt double-stranded miRNA duplexes which are 
loaded into Argonaute protein in the RNA induced silencing complex (RISC). After 
loading to RISC, double-stranded miRNA duplexes unwind and become a mature 
miRNA which is ready to target 3’UTRs of target mRNAs. Antisense oligonucleotide 
(antimiR) rapidly bind with the mature miRNA, causing the mature miRNA to be 
unable to detect to its target genes. Adapted from (Stenvang et al., 2012). 
 
	  
	  
	  
	  
 
 
 
 
 
	  
 
 
 
Figure 4.3. The RNA triple-strand design ensures specific microRNA mimicry. 
Only the miRNA guide strand is bound to RISC, displacing the mature RNA in the 
complex. Meanwhile, the complementary passenger strands are rapidly degraded. 
Figure and figure legend courtesy of Exiqon. Adapted from http://www.exiqon.com/mirna-
mimics. 
 
 
 
 
 
	  
	  
	  
	  
 
 
 
 
 
 
 
Figure 4.4. Pattern of miR-146a expression induced by M. tuberculosis H37Rv 
infection in (A) AMJ2.C11 and (B) IC-21 cells post miR-146a inhibitor or mimic 
transfection. AMJ2.C11 and IC-21 cells were transfected with either miR-146a 
mimic or mimic control or miR-146a inhibitor or scrambled control. After overnight 
incubation with IFNɣ, cells were infected with M.tb at an MOI of 1. 4 hours post 
infection unincorporated bacteria was washed away. At the indicated time points 
RNA was extracted using Trizol. The relative expression of miR-146a was measured 
by RT-qPCR was normalized to Let-7a and calculated using 2-△△Ct. Data are the mean 
± SEM of triplicate samples of one of two representative experiments. UI, uninfected; 
Differences between groups were analysed by one-way ANOVA *p<0.05, **p<0.01 
and ****p<0.0001. ns, not significant. 
 
 
 
 
	  
	  
	  
	  
 
 
 
 
 
 
Figure 4.5. Expression of miR-155 in (A) AMJ2.C11 and (B) IC-21 treated with 
miRNA-146a inhibitor or mimic and M.tb infection. AMJ2.C11 and IC-21 cells 
were transfected with either miR-146a mimic or mimic control or miR-146a inhibitor 
or scrambled control. Cells were incubated overnight with IFNɣ and infected with 
M.tb at an MOI of 1. 4 hours post infection unincorporated bacteria was washed off. 
At the indicated time points RNA was extracted. The relative expression of miR-155 
measured by RT-qPCR was normalized to Let-7a and determined using 2-△△Ct. miR-
146a inhibitor or mimic induced the same level of miR-155 as M. tb infection in 
AMJ2.C11 cells. In IC-21 cells, miR-146 mimic induced a higher level of miR-155 
than M. tb infection itself. Data are the mean ± SEM of triplicate samples of one of 
two representative experiments. UI, uninfected. Differences between groups were 
analysed by one-way ANOVA  ***p<0.001 and ****p<0.0001. 
 
 
 
	  
	  
	  
	  
 
 
 
 
 
	  
	  
	  
	  
 
 
 
 
 
 
 
 
 
 
 
Figure 4.6. The effects of miRNA-146a mimic and inhibitor on TNF expression 
from M.tb H37Rv - infected AMJ2.C11 cells. AMJ2.C11 cells were transfected with 
either the miR-146a mimic or miR-146a inhibitor or appropriate control. Cells were 
incubated overnight with IFNɣ before M.tb infection at an MOI of 1. 4-6 hours post 
infection unincorporated bacteria was washed off. At the indicated time points 
supernatant was collected. (A) The level of TNF (pg/ml) in AMJ2.C11 cells during 
the course of infection. (B) The statistical significance of silencing or overexpressing 
miR-146a on TNF levels in M.tb-infected AMJ2.C11 cells at each time point in 4.6A 
is demonstrated. Data are the mean ± SEM of triplicate samples of one of two 
representative experiments. Differences between groups were analysed by one-way 
ANOVA UI, uninfected; ns, not significant. *p<0.05, **p<0.01, ***p<0.001 and 
****p<0.0001. 
 
 
 
 
 
 
 
 
 
	  
	  
	  
	  
 
 
 
 
 
	  
	  
	  
	  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.7. The effects of miRNA-146a mimic and inhibitor on RANTES 
expression from M. tuberculosis H37Rv-infected AMJ2.C11 cells. AMJ2.C11 cells 
were transfected with either miR-146a mimic or miR-146a inhibitor, scramble control 
or mimic control. Cells were incubated with IFNɣ overnight before M .tuberculosis 
infection at an MOI of 1. (A) The level of RANTES (pg/ml) of AMJ2.C11 cells 
during the course of infection. (B) The amount of RANTES at each indicated time 
point. Data are the mean ± SEM of triplicate samples of one of two representative 
experiments. Differences between groups were analysed by one-way ANOVA, UI, 
uninfected; ns, not significant. *p<0.5, **p<0.01, ***p<0.001 and ****p<0.0001.  
 
 
 
 
 
 
 
 
 
 
	  
	  
	  
	  
 
 
 
Figure 4.8. The effects of miRNA-146a mimic and inhibitor on (A) MIP-1α and 
(B) MIP-1β expression from M. tuberculosis H37Rv-infected AMJ2.C11 cells. 
AMJ2.C11 cells were transfected with either miR-146a mimic or mimic control, miR-
146a inhibitor or scramble control. Cells were incubated overnight with IFNɣ  prior to 
M .tuberculosis infection at an MOI of 1. 4-6 hours post infection unincorporated 
bacteria was washed off. At the indicated time points supernatant was collected. Data 
are the mean ± SEM of triplicate samples of one of two representative experiments. 
Differences between groups were analysed by one-way ANOVA *p<0.05, **p<0.01 
and ****p<0.0001. ns; not significant. 
 
 
 
 
 
 
 
	  
	  
	  
	  
 
 
 
Figure 4.9. The effects of miRNA-146a mimic and inhibitor on (A) MIP-1α and 
(B) MIP-1β expression in M. tuberculosis H37Rv-infected IC-21 cells. IC-21 cells 
were transfected with either miR-146a mimic or mimic control, miR-146a inhibitor or 
scramble control. Cells were incubated with IFNɣ overnight before M.  tuberculosis 
infection at an MOI of 1. 4-6 hours post infection unincorporated bacteria was washed 
off. At the indicated time points supernatant was collected. Data are the mean ± SEM 
of triplicate samples of one of two representative experiments. Differences between 
groups were analysed by one-way ANOVA *p<0.05, **p<0.01 and ***p<0.001. 
 
 
 
 
	  
	  
	  
	  
 
Figure 4.10. The effects of miRNA-146a mimic and inhibitor on TNF expression 
in M. tuberculosis-infected IC-21 cells. IC-21 cells were transfected with either miR-
146a mimic or mimic control, miR-146a inhibitor or scramble control. After overnight 
incubation with IFNɣ, cells were infected with M. tuberculosis at an MOI of 1.  4-6 
hours post infection unincorporated bacteria was washed off. At the indicated time 
points supernatant was collected. Data are the mean ± SEM of triplicate samples of 
one of two representative experiments. Differences between groups were analysed by 
one-way ANOVA UI, uninfected; ns, not significant. *p<0.05, **p<0.01 and 
***p<0.001. 
 
 
	  
	  
	  
	  
 
 
Figure 4.11. The effects of miRNA-146a mimic and inhibitor on RANTES 
expression in M. tuberculosis-infected IC-21 cells. IC-21 cells were transfected with 
either miR-146a mimic or mimic control, miR-146a inhibitor or scramble control. 
After overnight incubation with IFNɣ, cells were infected with M. tuberculosis at an 
MOI of 1. 4-6 hours post infection unincorporated bacteria was washed off. At the 
indicated time points supernatant was collected. Data are the mean ± SEM of 
triplicate samples of one of two representative experiments. Differences between 
groups were analysed by one-way ANOVA ns, not significant. *p<0.05, **p<0.01 , 
***p<0.001 and ****p<0.0001. 
 
 
	  
	  
	  
	  
 
 
 
Figure 4.12. The effects of miRNA-146a mimic and inhibitor on intracellular M. t 
tuberculosis growth in (A) AMJ2.C11 and (B) IC-21 cells during the course of 
infection. Cells were transfected as indicated, incubated with IFNɣ, then infected with 
M. tuberculosis at an MOI of 1. 4-6 hours post infection unincorporated bacteria was 
washed off. At the indicated time points cells were treated with 0.1% Triton X-100 
followed by plating	   lysates on 7H11 agar. Data are the mean ± SEM of triplicate 
cultures of one of two representative experiments. Differences between groups were 
analysed by one-way ANOVA *p<0.05, **p<0.01 and ***p<0.001.  
 
 
 
 
	  
	  
	  
	  
 
 
